Therapeutic engineered nucleic acids and methods of use thereof

The engineered RNA, TY2, addresses the limitations of current therapies by enhancing macrophage function and stability, effectively reducing infarct size and managing inflammation, offering cardioprotection and sepsis mitigation.

WO2026236453A1PCT designated stage Publication Date: 2026-11-12CEDARS SINAI MEDICAL CENT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027049
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies for conditions such as myocardial infarction, sepsis, and arrhythmogenic cardiomyopathy are limited in their ability to reduce infarct size and manage inflammation and macrophage dysfunction, with no specific treatments available for sepsis beyond antibiotics, and existing strategies often fail to halt the progression of chronic cardiovascular diseases.

Method used

Development of a stable, chemically modified small non-coding RNA, TY2, derived from yREX3, which enhances macrophage efferocytosis and phagocytosis, reducing inflammation and organ dysfunction through increased stability and suitability for oral delivery using casein/chitosan formulations.

Benefits of technology

TY2 demonstrates cardioprotective and anti-inflammatory effects, reducing infarct size, improving macrophage function, and mitigating sepsis-induced organ damage, with enhanced stability and efficacy in treating myocardial infarction and sepsis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027049_12112026_PF_FP_ABST
    Figure US2026027049_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Several embodiments disclosed herein relate to engineered therapeutic nucleic acids and methods and compositions for treatment of a heart condition or an inflammatory condition using the same.
Need to check novelty before this filing date? Find Prior Art

Description

CSMC.027WO PATENTTHERAPEUTIC ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOFREFERENCE TO PRIOR APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 803398, filed on May 9, 2025, which is hereby incorporated by reference herein in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED R&D

[0002] This invention was made with government support under Grant No. R01 HL142579 and R01HL124074 awarded by the National Institutes of Health. The Government has certain rights in the invention.REFERENCE TO SEQUENCE LISTING

[0003] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled SequenceListingCSMC027WO.xml created on May 5, 2026, which is 25,613 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.BACKGROUND

[0004] The present disclosure generally relates to engineered nucleic acids (e.g„ small non-coding RNA) and uses thereof to treat inflammatory conditions and / or pathologies related to macrophage dysfunction. Non-limiting examples of conditions treated by administering the engineered nucleic acids include myocardial infarction (MI), sepsis, and arrhythmogenic cardiomyopathy (ACM).SUMMARY

[0005] This application is related to isolated nucleic acids comprising nucleobase sequences. Any features, structures, or steps disclosed herein can be replaced with or combined with any other features, structures, or steps disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the inventions havebeen described herein. Tt is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No individual aspects of this disclosure are essential or indispensable.

[0006] In some embodiments, an isolated nucleic acid comprising a nucleobase sequence comprising CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2) is provided. In some embodiments, a variant nucleobase sequence at least 90% identical to SEQ ID NO: 2 is provided with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the isolated nucleic acid is RNA, wherein the isolated nucleic acid is at most 35 nucleobases long. In some embodiments, the nucleobase sequence does not include or is not CCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:1). In some embodiments, the isolated nucleic acid comprises a nucleobase sequence that comprises CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO:2). In some embodiments, the isolated nucleic acid comprises an isolated nucleic acid comprising at least one chemically modified residue. In some embodiments, a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue. In some embodiments, the isolated nucleic acid comprises an isolated nucleic acid comprising 1-10 chemically modified residues. In some embodiments, the isolated nucleic acid comprises an isolated nucleic acid comprising at least one chemically modified residue within the 5’ half of the nucleobase sequence and / or at least one chemically modified residue within the 3’ half of the nucleobase sequence.

[0007] In some embodiments, the isolated nucleic acid comprises the chemically modified residue comprising a backbone modification. In some embodiments, the isolated nucleic acid comprises a backbone modification comprising a backbone sugar modification. In some embodiments, the chemically modified residue is a locked nucleic acid (LNA).

[0008] In some embodiments, the isolated nucleic acid comprises the isolated nucleic acid comprising the chemically modified residue at one or more of the first, third and fifth residues from the 3’ end and the 5’ end of the nucleobase sequence. In some embodiments, the nucleobase sequence comprises a LNA at the first, third and fifth residues from the 5’ end and the 3’ end. In some embodiments, the isolated nucleic acid comprises the nucleobasesequence comprising CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein each of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence is a LNA, In some embodiments, the isolated nucleic acid is 26 nucleobases in length,

[0009] Provided herein is an isolated nucleic acid comprising a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90% identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the nucleic acid is RNA. In some embodiments, the isolated nucleic acid comprises the nucleobase sequence comprising CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2). In some embodiments, the isolated nucleic acid comprises the isolated nucleic acid comprising at least one chemically modified residue. In some embodiments, a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue.

[0010] In some embodiments, the isolated nucleic acid comprises the isolated nucleic acid comprising 1-10 chemically modified residues. In some embodiments, the isolated nucleic acid comprising the isolated nucleic acid is at most 35 nucleobases long.

[0011] Also provided is an isolated nucleic acid consisting of a nucleobase sequence: CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, wherein each of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence is a LNA.

[0012] In some embodiments, a composition comprises the isolated nucleic acid of any one of the preceding claims; and a pharmaceutically acceptable excipient. In some embodiments, the composition comprises a transfection reagent. In some embodiments, the composition comprises the transfection reagent comprising one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, the composition comprises the transfection reagent comprising EV derived from cardiosphere-derived cells (CDC). In some embodiments, the composition comprises a casein phosphoprotein. In some embodiments, the composition comprises chitosan. In some embodiments, the composition comprises the isolated nucleic acidcomprising an encapsulated in a casein-chitosan complex. Tn some embodiments, the composition comprises casein micelles.

[0013] In some embodiments, the macrophage comprises the isolated nucleic acid wherein a cytoprotective activity of the macrophage is increased compared to a macrophage without the isolated nucleic acid. In some embodiments, the macrophage comprises the macrophage is in a subject. In some embodiments, the macrophage comprises a macrophage in culture. In some embodiments, the macrophage comprises the cytoprotective activity comprising efferocytosis and / or phagocytosis.

[0014] In some embodiments, a kit comprises a nucleic acid and a transfection reagent. In some embodiments, the transfection reagent comprises one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, a kit comprises a casein phosphoprotein and / or chitosan. In some embodiments, a method of treating a heart condition or symptom thereof, comprises administering to a subject in need of treating a heart condition or symptom thereof a therapeutically effective amount of an isolated nucleic acid or a composition thereby treating the heart condition or symptom thereof. In some embodiments, the heart condition comprises a symptom and / or sequelae of heart failure. In some embodiments, the heart condition comprises myocardial infarction (MI). In some embodiments, the heart condition comprises arrhythmogenic cardiomyopathy (ACM). In some embodiments, the heart condition comprises a symptom or sequelae of an infection. In some embodiments, the infection comprises sepsis.

[0015] In some embodiments, the subject, before the administering, has one or more of: elevated E / e’ ratio, decreased ejection fraction, increased bacterial load in the heart and / or lungs, enlarged spleen, wasting, elevated serum lactate and / or aspartate transferase (AST) levels, and elevated cytokine levels in the heart and / or lungs, increased frequency of ventricular arrhythmias, decreased cardiac conduction velocity, increased QRS, QT, QTc and / or action potential duration at 80% repolarization. In some embodiments, the method comprises identifying the subject in need of treating the heart condition or symptom thereof.

[0016] In some embodiments, a method of treating an inflammatory or fibrotic condition, comprises administering to a subject in need of treating an inflammatory or fibrotic condition a therapeutically effective amount of a nucleic acid or a composition thereby treatingthe inflammatory or fibrotic condition. Tn some embodiments, the inflammatory condition comprises an infection and / or symptom or sequelae thereof. In some embodiments, the infection comprises sepsis. In some embodiments, the symptom or sequelae of the infection comprises heart and / or lung dysfunction. In some embodiments, the method comprises identifying the subject in need of treating the inflammatory or fibrotic condition. In some embodiments, the inflammatory condition comprises immunosuppression subsequent to a hyperinflammatory response. In some embodiments, the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.

[0017] In some embodiments, the method comprises administering a therapeutically effective amount of the isolated nucleic acid comprising from about 0.001 mg / kg to about 100 mg / kg, or 0.01-1000 nM. In some embodiments, the method comprises administering the therapeutically effective amount of the isolated nucleic acid or the composition no more frequently than twice a week. In some embodiments, the method comprises administering a therapeutically effective amount of the isolated nucleic acid or the composition intravenously, intramuscularly, intracardially, or orally. In some embodiments, the method of immunomodulation, comprises contacting an effective amount of the isolated nucleic acid or a composition with a population of macrophages, to thereby modulate an antiinflammatory activity of macrophages of the population. In some embodiments, the contacting comprises administering to a subject in need of treating an inflammatory condition an effective amount of the isolated nucleic acid or the composition, to thereby modulate an antiinflammatory activity of macrophages in the subject. In some embodiments, the macrophage is a human macrophage.

[0018] In some embodiments, the isolated nucleic acid or the composition is for treatment of a heart condition or symptom thereof in a subject in need thereof. In some embodiments, the heart condition comprises myocardial infarction (MI) or arrhythmogenic cardiomyopathy (ACM).

[0019] In some embodiments, the isolated nucleic acid or the composition is for treatment of an inflammatory and / or fibrotic condition in a subject in need thereof. In some embodiments, the inflammatory condition comprises sepsis and / or symptom or sequelae thereof. In some embodiments, the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.BRIEF DESCRIPTION OF THE DRAWINGS

[0020] FIG. 1A shows a schematic diagram of mechanism of action of yREX3 in myocardial infarction (MI).

[0021] FIG. IB shows a schematic diagram of two-step screening of yREX3-derived structural variants for optimization of activity. Step 1 (primary modifications): mutagenesis; step 2 (secondary modifications): the inclusion of locked nucleic acids (LNA, underlined).

[0022] FIGs. 1C and ID are graphs showing the effects of the yREX3-derived structural variants on pick 1 expression in rat bone marrow derived macrophage (BMDM) according to some non-limiting embodiments of the present disclosure. FIG. 1C is a graph of pickl expression in rat BMDM exposed to the test compounds for 24 hours (80nM). FIG. ID is a graph of pickl expression in rat BMDM exposed to the test compounds for 48 hours (80nM) (n=3-4 biological replicates per group).

[0023] FIG. 2A shows a schematic diagram of the structure-activity optimization studies conducted to develop the lead candidate, TY2, from yREX3, the naturally occurring therapeutically bioactive small Y RNA.

[0024] FIG. 2B shows graphs of the stability of yREX3 and TY2 in RNAse protection assays according to some non-limiting embodiments of the present disclosure. FIG.2B shows graphs of Ct cycles for yREX3 and TY2 exposed to increasing concentrations of the exonuclease, RNAse R, after 1 and 2 hours of incubation (n=3 biological replicates per group).

[0025] FIGs. 3A and 3B show the effects of the yREX-derived structural variants on efferocytosis in an assay showing the capacity of TY2-exposed macrophages to uptake DiD-labeled dead-rat cardiomyocytes (CM) according to some non-limiting embodiments of the present disclosure. FIG. 3A shows representative images taken at 48 hours. FIG. 3B shows a graph of the fold change (FC) in macrophage uptake of DiD-labeled CMs compared to vehicle (n=3 biological replicates / group).

[0026] FIG. 4A shows a schematic diagram of the yREX3 oral formulation.

[0027] FIG. 4B shows a schematic diagram of the timeline of myocardial infarction (MI) and treatment (Tx). Rats underwent myocardial infarction (MI, induced by 45 min ofischemia followed by reperfusion). 20 minutes after reperfusion the rats received saline, yREX3 or TY2 orally by gavage.

[0028] FIGs. 4C-4E show cardioprotective activity for both yREX3 and TY2, formulated for oral delivery, 48 hours post-myocardial infarction (MI) compared to animals injected with vehicle or sham (n=3-7 animals / group, mean ± SEM), according to some nonlimiting embodiments of the present disclosure. FIG. 4C shows yREX3 and TY2 both reduced MI size as shown by images of scar mass measured by triphenyltetrazolium chloride (TTC) staining (representative images). FIG. 4D is a graph showing yREX3 and TY2 both reduced infarct mass. FIG. 4E is a graph showing yREX3 and TY2 both reduced circulating cardiac troponin I levels (cTnl).

[0029] FIG. 5A shows a schematic diagram of the timeline of the Caecal ligation puncture (CLP)-induced polymicrobial sepsis model with induction at day 0. Sham mice were submitted to the same procedures without caecal puncture. TY2 or vehicle were administered intravenously at day 1, 3 and 5 and mice were sacrificed at day 7 for endpoint analyses.

[0030] FIG. 5B shows a survival curve for animals subjected to different treatments by intravenous injection (IV inj) according to some non-limiting embodiments of the present disclosure.

[0031] FIG. 5C shows a graph of body weights (BW, grams) of animals recorded at day 0 (before caecal ligation and puncture (CLP) procedure) and at endpoint (day 7) according to some non-limiting embodiments of the present disclosure.

[0032] FIG. 5D shows a graph of Organs’ weights (OW) normalized by tibia length (TL) of animals exposed to different treatment regimens at endpoint (day 7) according to some non-limiting embodiments of the present disclosure.

[0033] FIG. 5E shows a graph of echocardiographic measurement of ejection fraction (EF, %) after CLP induction and before the first injection (day 1) and at day 7 according to some non-limiting embodiments of the present disclosure.

[0034] FIG. 5F shows a graph of echocardiographic measurement of fractional shortening (FS, %) after caecal ligation and puncture (CLP) induction and before the first injection (dayl) and at day 7 according to some non-limiting embodiments of the present disclosure.

[0035] FIG. 5G shows a graph of restoration of ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity (E / E’) in caecal ligation and puncture (CLP) at day 1 (before treatment) and day 7 according to some non-limiting embodiments of the present disclosure.

[0036] FIG. 5H shows a graph of left ventricular internal dimension (LVID) measurements used to assess left ventricular function decrease in TY2 compared to vehicle-treated caecal ligation and puncture (CLP) mice, according to some non-limiting embodiments of the present disclosure.

[0037] FIG. 51 shows a graph of the decrease in heart bacterial 16S load, referred to as the quantity of bacterial DNA detected in the sample, in TY2-treated mice compared to vehicle according to some non-limiting embodiments of the present disclosure.

[0038] FIG. 5 J shows a graph of the decrease in lung bacterial 16S load, referred to as the quantity of bacterial DNA detected in the sample, in TY2-treated mice compared to vehicle according to some non-limiting embodiments of the present disclosure.

[0039] FIG. 5K shows a graph of decrease of expression levels of clinically relevant cytokines in heart in TY2-treated mice compared to vehicle at day 7 as detected by qPCR (data presented as fold change (FC) compared to sham animals) according to some nonlimiting embodiments of the present disclosure. For each cytokine, each bar from left to right corresponds to “Sham”, “Veh”, or “TY2”.

[0040] FIG. 5L shows a graph of decrease of expression levels of clinically relevant ILlbeta in lungs in TY2-treated mice compared to vehicle at day 7 as detected by qPCR (data presented as fold change (FC) compared to sham animals) according to some non-limiting embodiments of the present disclosure. For each cytokine, each bar from left to right corresponds to “Sham”, “Veh”, or “TY2”.

[0041] FIG. 5M are immunofluorescence images of bone marrow derived macrophages (BMDMs) showing enhanced capacity of BMDMs exposed to TY2 in vitro to phagocytize E. coli particles in an in vitro assay according to some non-limiting embodiments of the present disclosure.

[0042] FIG. 5N shows a graph of increase in phagocytosis of E. coli particles by bone marrow derived macrophages (BMDMs) exposed to TY2 in vitro compared to vehicle according to some non-limiting embodiments of the present disclosure.

[0043] FIGs. 6A-6C show cardioprotective activity for both yREX3 and TY2, administered intravenously (IV) and orally by gavage, 48 hours post-myocardial infarction (MI) compared to vehicle- (Veh) treated animals according to some non-limiting embodiments of the present disclosure. FIG. 6A shows yREX3 and TY2 both reduced MI size as shown by images of scar mass measured by triphenyltetrazolium chloride (TTC) staining (representative images). FIG. 6B is a graph showing both IV and oral yREX3 and TY2 reduced infarct mass. FIG. 6C is a graph showing both IV and oral yREX3 and TY2 reduced circulating cardiac troponin I levels (cTnl).

[0044] FIG. 7A shows immunofluorescence images of pSMAD3 and CD68 in heart sections of mice subjected to Cecal ligation puncture (CLP)-induced polymicrobial sepsis model (FIG. 5 A) 72 hrs after receiving vehicle- or TY2- treatment.

[0045] FIG. 7B shows measurement of pSmad3 expression in images of heart sections of mice subjected to cecal ligation puncture model (CLP)-induced polymicrobial sepsis (FIG. 5A) 72 hrs after receiving vehicle- or TY2- treatment. Data presented as mean ± SEM, dots represent single animals; analysis of two groups was done using a Student’s unpaired t test with 95% CI.

[0046] FIG. 7C shows serum lactate levels in mice subjected to cecal ligation puncture model (CLP)-induced polymicrobial sepsis (FIG. 5A) 72 hours after receiving vehicle- or TY2- treatment compared to Sham. Statistic analysis was done using One-Way ANOVA with Tukey’s post test to control for multiple comparisons; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.

[0047] FIG. 7D shows AST levels, indicating hepatic dysfunction, in mice subjected to cecal ligation puncture model (CLP)-induced polymicrobial sepsis (FIG. 5A) 72 hours after receiving vehicle- or TY2- treatment compared to Sham. Statistic analysis was done using One-Way ANOVA with Tukey’s post test to control for multiple comparisons; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.

[0048] FIG. 7E shows glucose levels in mice subjected to cecal ligation puncture model (CLP)-induced polymicrobial sepsis (FIG. 5A) 72 hours after receiving vehicle- or TY2-treatment compared to Sham. Data presented as mean ± SEM, with dots representing single animals. Statistic analysis was done using One-Way ANOVA with Tukey’s post test to control for multiple comparisons; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.

[0049] FIG. 7F shows automated fluorescence reading assessment of bacterial (E. coli) clearance by bone marrow derived macrophages (BMDMs) from male mice 48 hours after exposure to vehicle or different concentrations of TY2 (40nM, 80nM). Statistic analysis of three groups was done using One-Way ANOVA with Dunnett’s post-test; **p<0.01, ***p<0.001, and ****p<0.0001).

[0050] FIG. 7G shows automated fluorescence reading assessment of bacterial (E. coli) clearance by bone marrow derived macrophages (BMDMs) from female mice 48 hours after exposure to vehicle or different concentrations of TY2 (40nM, 80nM). Statistic analysis of three groups was done using One-Way ANOVA with Dunnett’s post-test; **p<0.01, ***p<0.001, and ****p<0.0001).

[0051] FIG. 7H shows phagocytotic capacity over time with a peak at 48 hrs. Data presented as mean ± SEM, with dots representing independent readings. Statistic analysis of two groups was done using a Student’s unpaired t test with 95% CI.

[0052] FIG. 8A shows a schematic diagram of treatment protocol of adult Desmoglein-2 (DSG2) mutant mice with intravenous TY2 or placebo two times a week.

[0053] FIG. 8B shows representative M-mode echocardiograms in vehicle- (top) and TY2- (bottom) treated adult Desmoglein-2 (DSG2) mutant mice.

[0054] FIG. 8C shows a graph of echocardiographic measurement of ejection fraction (EF, %) in vehicle- and TY2- treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0055] FIG. 8D shows a graph of Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) in vehicle- and TY2- treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0056] FIG. 9A shows representative electrocardiograms (ECGs) in vehicle- and TY2- treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0057] FIG. 9B shows a graph of QRS duration (ms) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0058] FIG. 9C shows a graph of QT duration (ms) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4-5 mice / group. Unpaired student t-test.

[0059] FIG. 9D shows a graph of QTc (ms) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0060] FIG. 10A shows representative electrocardiogram (ECG) pacing protocols in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some nonlimiting embodiments of the present disclosure.

[0061] FIG. 10B shows a graph of percent inducibility of ventricular tachycardia (VT) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0062] FIG. 11A shows a graph of premature ventricular contraction (PVC) (counts / hour) over 24 hours in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0063] FIG. 1 IB shows a graph of premature ventricular contraction (PVC) burden (Count) over 24 hours in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0064] FIG. 12A shows representative activation maps of the heart in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0065] FIG. 12B shows a graph of ventricular conduction velocity (CV)(cm / s) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some nonlimiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0066] FIG. 12C shows a graph of action potential duration at 80% repolarization (APD80) (ms) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group. Unpaired student t-test.

[0067] FIG. 13A shows a graph of fold change of fibrosis marker genes in vehicle-and TY2-treated adult Desmoglein-2 (DSG2) mutant mice relative to wild type according to some non-limiting embodiments of the present disclosure.

[0068] FIG. 13B shows representative images of ventricular interstitial and perivascular fibrosis in cardiac tissue measured by Masson Trichome staining in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure.

[0069] FIGs.l3C-13D show graphs of ventricular interstitial fibrosis (%) and ventricular perivascular fibrosis (%) in vehicle- and TY2-treated adult Desmoglein-2 (DSG2) mutant mice according to some non-limiting embodiments of the present disclosure. n=4 mice / group, 5-6 images / heart. Unpaired student t-test.

[0070] FIG. 14A shows a schematic diagram of the study design for evaluating the effects of TY2 treatment on peripheral blood mononuclear cells (PBMC) from Desmoglein-2 (DSG2) mutant mice.

[0071] FIG. 14B shows a graph of TY2 levels (Fold Count (FC) to Veh) in PBMCs from Desmoglein-2 (DSG2) mutant mice treated with Vehicle or TY2. n=4 mice / group. Unpaired student t-test.

[0072] FIGs.l4C and 14D show graphs of pickl (FIG. 14C) and IL-6 (FIG. 14D) levels (Fold Count (FC) in PBMCs from Desmoglein-2 (DSG2) mutant mice treated with Vehicle or TY2. n=4 mice / group. Unpaired student t-test.

[0073] FIG. 15A shows a schematic diagram of the study design for evaluating in vitro effects of TY2 treatment on efferocytosis of macrophage from Desmoglein-2 (DSG2) mutant mice in an assay showing the capacity of TY2-exposed macrophages to uptake DiD-labeled dead-rat cardiomyocytes (CM) according to some non-limiting embodiments of the present disclosure.

[0074] FIGs. 15B and 15C show the effects of the TY2 on efferocytosis of macrophage from Desmoglein-2 (DSG2) mutant mice in an assay showing the capacity of macrophages to uptake DiD-labeled dead-rat cardiomyocytes (CM). FIG. 15B shows representative images taken at 48 hours post treatment. FIG. 15C shows a graph of the fold change (FC) in macrophage uptake of DiD-labeled CMs compared to vehicle. n=4 mice / group. Unpaired student t-test.

[0075] FIGs.16A and 16B show toxicity testing of TY2 treatment on male and female Desmoglein-2 (DSG2) mutant mice compared to Vehicle. FIG. 16A shows a graph of endpoint body weight (grams) of mice treated with Vehicle or TY2. n=3 mice / group. Unpaired student t-test. FIG. 16B shows a graph of serum laboratory values in mice 6 weeks after systemic treatment with TY2 or vehicle. Units for each marker provided in parentheses with the marker label on the x axis.DETAILED DESCRIPTION

[0076] MI is an acute event that precipitates chronic cardiovascular disease. To date, current strategies either alleviate symptoms or, at best, slow the progress of disease progression. As such, therapeutics that reduce infarct size have the potential to stem the tide of downstream cardiovascular diseases including heart failure. For sepsis-induced inflammation and organ dysfunction, despite the high mortality rate, no specific treatment modality or drugs with high efficacy is available for sepsis to date, besides the use of antibiotics.

[0077] Percutaneous coronary intervention (PCI) has become standard therapy for patients with MI, reducing acute mortality and improving long-term clinical outcomes. Nevertheless, many MI patients, particularly those who end up with a large infarct size (IS), progress to heart failure (HF), even with the best current therapy.

[0078] Inflammatory diseases (including systemic sepsis and pulmonary fibrosis) affect a large subset of the world population, particularly in the United States. Sepsis is a lifethreatening organ dysfunction syndrome caused by dysregulated host response to infection that leads to uncontrolled inflammatory response followed by immunosuppression. However, despite the high mortality rate, no specific treatment modality or drugs with high efficacy is available for sepsis to date. Reduction in inflammation and organ dysfunctions caused by a polymicrobial sepsis model is sought.

[0079] Provided herein is a novel engineering of a small non-coding RNA drug, TY2, which derives from a naturally occurring small non-coding RNA, yREX3 (that was found to be enriched in extracellular vesicles from therapeutically potent cardiosphere-derived cells, CDCs). As used herein, reference “yREX3” herein denotes a nucleic acid having the nucleotide sequence of SEQ ID NO:2 (without chemical modification), unless indicated otherwise. yREX3 triggers profound transcriptomic effects in monocyte-derived macrophagescompared to other cell types in the heart. Specifically, yREX3 silences Pickl expression through gene methylation. Pickl is an endocytic accessory protein involved in receptor recycling. Pickl suppression in macrophages leads to hyperphosphorylation of Smad3 and enhances their ability to clear dead cells, a process called efferocytosis. The engineered and more stable form of yREX3, TY2, shows therapeutic efficacy in rat and mouse models.

[0080] The present disclosure shows that TY2 exhibits higher stability compared to the naturally occurring small RNA (e.g., yREX3) and includes LNA-locked nucleic acids in its structure that makes it resistant to degradation by RNases for in vivo delivery. As shown herein, TY2 is also suitable for oral delivery using an oral formulation, such as those containing casein / chitosan. As shown herein, TY2 provides anti-inflammatory and cytoprotective effects in multiple organ systems including the heart and lungs. TY2 increases phagocytosis of bacteria by macrophages and is cardioprotective against myocardial infarction (MI). TY2 is also protective of the heart and lungs from sepsis. The structure (e.g., sequence) of TY2 is provided in SEQ ID NO: 5 (see, Table 1 and FIG. IB).

[0081] Provided herein is an isolated nucleic acid, e.g., RNA, that includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), sequence variants and / or chemical modifications thereof, and methods of use thereof. In some embodiments, the isolated nucleic acid includes at least one non-natural chemical modification. In general, the present nucleic acids are 35 nt long or shorter (e.g., 16-35 nt long, or 20-30 nt long). In some embodiments, the isolated nucleic acid is TY2 (SEQ ID NO: 5), or a sequence variant thereof. In general, a variant, e.g., a sequence variant or chemical modification, of the nucleic acid includes variants and chemical modifications that are functional. Thus, sequence variations and chemical modifications contemplated are those that substantially preserve the therapeutic potency of the original molecule (e.g., having a nucleobase sequence of SEQ ID NO: 2). In some embodiments, the isolated nucleic acid is set forth in SEQ ID NO: 5.

[0082] Nucleic acids of the present disclosure, e.g., TY2 and / or variants thereof, find use in treating conditions where inflammation and / or macrophage dysfunction are the main drivers of pathology. In some embodiments, conditions treated by nucleic acids of the present disclosure, e.g., TY2, include, without limitation, inflammatory disease, sepsis, or cardiac injury. In some embodiments, the present nucleic acids, e.g., TY2, have cardioprotective effects when administered to a subject suffering from cardiac injury due to,without limitation, myocardial infarction and / or heart failure. In some embodiments, the present nucleic acids, e.g., TY2, have therapeutic effects for cardiac arrhythmia, such as but not limited to arrhythmogenic cardiomyopathy (ACM).

[0083] In some embodiments, nucleic acids of the present disclosure are chemically modified to increase stability, e.g., in vivo and / or in vitro stability. In some embodiments, nucleic acids of the present disclosure are chemically modified to reduce immunogenicity. In some embodiments, the chemical modification of the nucleic acids increases the therapeutic activity of the nucleic acids. In some embodiments, nucleic acids of the present disclosure have enhanced therapeutic potency compared to endogenously encoded RNA molecules, e.g., endogenously encoded non-coding RNA such as yREX3. Nucleic acids of the present disclosure in some embodiments can be provided in a composition (e.g., pharmaceutical compositions) or a kit.Terms

[0084] As used herein “nucleic acid” and “oligonucleotide” have their customary and ordinary meaning as understood by one of ordinary skill in the art in view of the present disclosure. “Nucleic acid” and “oligonucleotide” refer to multiple nucleotides (e.g., molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G))), or analogues thereof. Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are nucleic acids in which the nucleotides are linked through a 3 '.5 '-phosphodiester bond to form a backbone of alternating phosphate groups and sugar moiety. RNA is composed of ribose sugar groups and DNA is composed of deoxyribose sugar groups. A nucleic acid includes polynucleosides (e.g.. a polynucleotide minus the phosphate) and any other organic basecontaining polymer. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, inosine, 5 -methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Chemical modifications can be introduced at the site of the phosphodiester bond, sugar moiety, nucleobase, or combined sites thereof. Phosphorothioate (PS) oligonucleotides, are nucleic acids with a modified phosphate in whichone of the non-bridging oxygens of the phosphate-ester group is changed to sulfur. This modification retains the negative charge of the backbone. They can have highly increased nuclease resistance relative to the natural nucleic acids. 2’-0-methylation is a modification on the ribose sugar of RNA in which a methyl group is added to the 2’ hydroxyl group of the native RNA. In “locked” nucleic acids (LNAs) the 2'-oxygen is attached to the 4'-carbon of the ribose sugar via a methylene bridge that locks in an RNA-like C3’-endo conformation. These derivatives are also known as 2',4'-bridged nucleic acids (BNA). The methylene bridge fixes the furanose ring in the 3'-endo conformation that is highly advantageous for base pairing. LNA can form very stable duplexes with RNA and DNA according to the Watson-Crick rule with excellent selectivity. The incorporation of LNA monomers into DNA oligomer can increase the strength of hybridization. A nucleic acid can include any other suitable modifications. Thus, the term nucleic acid also encompasses nucleic acids with substitutions or modifications, such as in the bases and / or sugars. Nucleic acid includes nucleotide analogues and polymers thereof, including, but not limited to. a polynucleoside in which two nucleosides are linked by a non-phosphodiester bond, e.g., linked by a phosphorothioate bond. “RNA molecule” as used herein denotes a nucleic acid that includes ribose as the sugar component, and derivatives thereof, including a nucleic acid that has been modified at the site of the phosphodiester bond, sugar moiety, nucleobase, or combined sites thereof. As used herein, a “nucleobase sequence” denotes a sequence of nucleobases (e.g., cytosine (C), thymidine (T) / uracil (U), adenine (A) or guanine (G)) consecutively ordered along a backbone structure in a nucleic acid, e.g., along a sugar-phosphate backbone structure.

[0085] Nucleic acid molecules of the present disclosure may share a certain degree of sequence similarity or identity with the reference molecules (e.g., reference nucleic acids), for example, with art-described molecules (e.g., engineered or designed molecules or wildtype molecules). The term “identity” as known in the art, refers to a relationship between the sequences of two or more nucleic acids, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between them as determined by the number of matches between strings of two or more nucleic acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., “algorithms”). Identity of related peptides can be readily calculated by known methods. “%identity” as it applies to nucleic acid sequences is defined as the percentage of residues (nucleic acid residues) in the candidate nucleic acid sequence that are identical with the residues in the nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Any suitable methods and computer programs for the alignment can be used. It is understood that identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation. Generally, variants of a particular nucleic acid have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%, 99% but less than 100% sequence identity to that particular reference nucleic acid as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al (1997), “Gapped BLAST and PSLBLAST: a new generation of protein database search programs”. Nucleic Acids Res. 25:3389-3402). Another popular local alignment technique is based on the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981) “Identification of common molecular subsequences.” I. Mol. Biol. 147:195-197.) A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, S. B. & Wunsch. C. D. (1970) “A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443-453.). More recently a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) has been developed that purportedly produces global alignment of nucleotide and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Other tools are described herein, specifically in the definition of “identity” below.

[0086] The term “identity” refers to the overall relatedness between polymeric molecules, for example, between nucleic acid molecules (e.g. DNA molecules and / or RNA molecules). Calculation of the percent identity of two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%. at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotidepositions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a suitable mathematical algorithm. For example, the percent identity between two nucleic acid sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M„ ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects. Smith. D. W., ed., Academic Press. New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleic acid sequences can be determined using the algorithm of Meyers and Miller (CAB IOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleic acid sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol.. 215, 403 (1990)).

[0087] The term “Watson-Crick base-pairing”, or “base-pairing” refers to the formation of hydrogen bonds between specific pairs of nucleotide bases (“complementary base pairs”). For example, two hydrogen bonds form between adenine (A) and uracil (U), and three hydrogen bonds form between guanine (G) and cytosine (C). One method of assessing thestrength of bonding between two nucleic acid molecules is by quantifying the percentage of bonds formed between the guanine and cytosine bases of the two nucleic acid molecules (“GC content”). In some embodiments, the GC content of bonding between two nucleic acids of a multimeric molecule (e.g., a multimeric mRNA molecule) is at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. In some embodiments, the GC content of bonding between two nucleic acids of a multimeric molecule (e.g., a multimeric mRNA molecule) is between 10% and 70%, about 20% to about 60%, or about 30% to about 60%. The formation of a nucleic acid duplex via bonding of complementary base pairs can also be referred to as “hybridization”. Generally, two nucleic acids sharing a region of complementarity are capable, under suitable conditions, of hybridizing (e.g., via nucleic acid base pairing) to form a duplex structure. A region of complementarity can vary in size. In some embodiments, a region of complementarity ranges in length from about 2 base pairs to about 100 base pairs. In some embodiments, a region of complementarity ranges in length from about 5 base pairs to about 75 base pairs. In some embodiments, a region of complementarity ranges in length from about 10 base pairs to about 50 base pairs. In some embodiments, a region of complementarity ranges in length from about 20 base pairs to about 30 base pairs.

[0088] “Isolated” as used herein with reference to an isolated biomolecule, e.g., a nucleic acid, has the ordinary and customary meaning to one of ordinary skill in the art in view of the present disclosure. An isolated biomolecule, e.g., an isolated nucleic acid, is generally in a non-natural environment, or in an environment that the biomolecule would otherwise not have been without human intervention of the biomolecule or its environment. In some embodiments, an isolated biomolecule is not inside a cell or an organism.

[0089] “Extracellular vesicle” or “EV” as used herein have their ordinary and customary meaning as understood by one of ordinary skill in the art, in view of the present disclosure. EVs include lipid bilayer structures generated by cells, and include exosomes, microvesicles, epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.

[0090] “Micelle,” as used herein with reference to casein micelles, has its customary and ordinary meaning as understood by one of ordinary skill in the art, in view of the present disclosure. Casein micelles are colloidal particles that can include aggregates ofone or more casein phosphoproteins (e.g., one or more, two or more, three or more, or all four of alpha si casein, alpha s2 casein, beta casein, and kappa casein).

[0091] “Subject,” as used herein refers to any vertebrate animal, including mammals and non-mammals. A subject can include primates, including humans, and nonprimate mammals, such as rodents, domestic animals or game animals. Non-primate mammals can include mouse, rat, hamster, rabbit, dog. fox, wolf, cat, horse, cow, pig, sheep, goat, camel, deer, buffalo, bison, etc. Non-mammals can include bird (e.g., chicken, ostrich, emu, pigeon), reptile (e.g., snake, lizard, turtle), amphibian (e.g., frog, salamander), fish (e.g., salmon, cod, pufferfish, tuna), etc. The terms, “individual,” “patient,” and “subject” are used interchangeably herein.

[0092] “Administering” as used herein can include any suitable routes of administering a therapeutic agent or composition as disclosed herein. Suitable routes of administration include, without limitation, oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, cutaneous, injection or topical administration. Administration can be local or systemic.

[0093] As used herein, “treat” and “treatment” includes curing, improving, ameliorating, reducing the severity of, preventing, slowing the progression of, and / or delaying the appearance of a disease, condition and / or symptoms thereof. “Treating” or “treatment” as used herein refers to altering one or more of the signs or symptoms of a condition, e.g., disease, described herein in a beneficial manner; improving or ameliorating other clinically accepted symptoms, e.g., by at least 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%. 100%. 150%. or 200% or more; or inducing a desired response, by performing methods described herein. Efficacy of treatment can be assessed, for example, by measuring a marker, indicator, symptom, and / or the incidence of a condition treated according to the methods described herein or any other measurable parameter appropriate, e.g.. circulating cTnl levels, body weight, ejection fraction, E / E’ ratio, fractional shortening, left ventricular internal dimension, etc. Efficacy of treatment can also be measured by a failure of an individual to worsen as assessed by hospitalization, or need for medical interventions (e.g., progression of the disease is halted). Treatment includes any treatment of a disease in an individual or an animal (some non-limiting examples include a human or an animal) and includes: (1) inhibiting the disease, e.g., preventing a worsening of symptoms (e.g. pain or inflammation); or (2)relieving the severity of the disease, e.g., causing regression of symptoms. Treating includes, in some embodiments, healing or repairing a tissue or organ damaged or impaired by or as a consequence of a disease or other impact of a disease, e.g., inflammatory conditions. A therapeutically effective amount for the treatment of a disease means that amount which, when administered to a subject in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease. Efficacy of an agent can be determined by assessing physical indicators of a condition or desired response, (e.g., cardiac function). One skilled in the art can monitor efficacy of administration and / or treatment by measuring any one of such parameters, or any combination of parameters.

[0094] A treatment can be considered “effective,” or “therapeutically effective” as used herein, if one or more of the signs or symptoms of a condition described herein are altered in a beneficial manner, other clinically accepted symptoms are improved, or even ameliorated, or a desired response is induced e.g., by at least 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%. 70%, 80%, 90%, 100%, 150%, or 200%. or more, following treatment according to the methods described herein. Efficacy can be assessed, for example, by measuring a marker, indicator, symptom, and / or the incidence of a condition treated according to the methods described herein or any other measurable parameter appropriate, e.g. circulating cTnl levels, body weight, ejection fraction, E / E’ ratio, fractional shortening, left ventricular internal dimension, etc. Efficacy can also be measured by a failure of an individual to worsen as assessed by hospitalization, or need for medical interventions (e.g., progression of the disease is halted).

[0095] The term “effective amount” as used herein refers to the amount of a composition or an agent (e.g., nucleic acid) needed to provide the desired effect, e.g., cellular response, therapeutic effect, etc. The term “therapeutically effective amount” as used herein refers to the amount of a composition or an agent (e.g., nucleic acid) needed to alleviate at least one or more symptom of the disease or condition, and relates to a sufficient amount of therapeutic composition to provide the desired effect. The term “therapeutically effective amount” can refer to an amount of a composition or therapeutic agent that is sufficient to provide a particular anti-inflammatory and / or cardioprotective effect when administered to a typical subject. A therapeutically effective amount as used herein, in various contexts, can include an amount sufficient to delay the development of a symptom of the disease orcondition, alter the course of a symptom disease or condition (for example but not limited to, slowing the progression of a symptom of the disease or condition), or reverse a symptom of the disease or condition. In some embodiments, the therapeutically effective amount is administered in one or more doses of the therapeutic agent. In some embodiments, the therapeutically effective amount is administered in a single administration, or over a period of time in a plurality of doses.

[0096] As used herein, the phrase “physiologically compatible” and “pharmaceutically acceptable” are employed interchangeably herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0097] Definitions of common terms in cell biology and molecular biology can be found in “The Merck Manual of Diagnosis and Therapy”. 19th Edition, published by Merck Research Laboratories, 2006 (ISBN 0-91 1910-19-0); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Benjamin Lewin, Genes X, published by Jones & Bartlett Publishing, 2009 (ISBN-10: 0763766321); Kendrew et al. (eds.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8) and Current Protocols in Protein Sciences 2009, Wiley Inter sciences, Coligan et al., eds.

[0098] The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. The abbreviation, “e.g.” is used herein to indicate a non- limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” The term “about” as used herein to, for example, define the values and ranges of molecular weights means that the indicated values and / or range limits can vary within ±20%, e.g., within ±10%, including within ±5%. The use of “about” before a number includes the number itself. For example, “about 5” provides express support for “5.” Numbers provided in ranges include overlapping ranges and integers in between; for example a range of 1-4 and 5-7 includes for example, 1-7, 1-6, 1-5, 2-5, 2-7, 4-7, 1, 2, 3, 4, 5, 6 and 7.NUCLEIC ACIDS

[0099] Provided herein is an isolated nucleic acid that includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or a variant thereof. In some embodiments, the isolated nucleic acid is RNA. In some embodiments, the nucleic acid includes a nucleobase sequence at least 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 98%. or 99% identical to CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2). In some embodiments, the nucleic acid includes a nucleobase sequence at least 90% identical to CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2). In some embodiments, the nucleic acid includes a nucleobase sequence at least 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 98%, 99% identical to CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), with the proviso that when position 26 of the nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2. For example, if position 26 of the nucleobase sequence as numbered according to SEQ ID NO:2 is uracil , then at least one (e.g„ 1. 2, 3 or more) of the residues 1-25 of the nucleobase sequence as numbered according to SEQ ID NO:2 is different from the corresponding residue in SEQ ID NO:2. In some embodiments, the nucleic acid includes a nucleobase sequence at least 90% identical to CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), with the proviso that when position 26 of the nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2. In some embodiments, the nucleic acid includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2) with 1, 2, 3, 4, or 5 substitutions thereto. In some embodiments, the nucleic acid includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2) with 2, 3, 4, or 5 substitutions thereto, with the proviso that when position 26 of the nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the nucleobase sequence comprises at least one (e.g., 1, 2, 3, 4) other substitution relative to SEQ ID NO:2. As used herein, a “position” within a nucleobase sequence or nucleic acid is defined relative to the 5’ end of the nucleobase sequence or nucleic acid, unless indicated otherwise. In some embodiments, the first position of the nucleobase sequence (as numbered according to SEQ ID NO:2) is not G. In some embodiments, the nucleobase sequence of the nucleic acid is not yREX3. In someembodiments, the nucleobase sequence of the isolated nucleic acid does not include or is not CCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:1). In some embodiments, the nucleobase sequence of the nucleic acid is or includes CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or a sequence variant thereof. In some embodiments, the nucleobase sequence is or includes CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:4). The nucleic acid can be any suitable length. In some embodiments, the nucleic acid is 26 nucleobases in length. In some embodiments, the nucleic acid is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleobases in length, or longer. In some embodiments, the nucleic acid is at most 35 nucleobases long. In some embodiments, the nucleic acid is 16-35 nucleobases long, or 20-30 nucleobases long.

[0100] A nucleic acid of the present disclosure can be single stranded or double stranded (e.g., RNA / DNA hybrid). In some embodiments, the nucleic acid is single stranded. As used herein, “single stranded” denotes that the nucleic acid, e.g., RNA, is not hybridized to or annealed to another nucleic acid molecule. In some embodiments, the single stranded RNA includes one or more portions that can hybridize or anneal to itself. In some embodiments, the single stranded RNA includes one or more portions that can form a stem-loop structure by hybridizing or annealing to itself.

[0101] An isolated nucleic acid of the present disclosure in some embodiments includes one or more chemically modified residues, e.g., nucleotides with a modified backbone. As used herein, “chemical modification” refers to a difference in the chemical structure of the residues of the nucleic acid relative to the corresponding naturally occurring nucleotides (e.g., adenine, guanine, uracil, thymidine, cytosine nucleotides). A chemical modification can be a natural modification or an artificial modification of the chemical structure of the naturally occurring nucleotides. In general, the chemical modification(s) is one that substantially preserves or enhances the therapeutic potency of the nucleic acid. Any suitable number of residues of the nucleic acid can be chemically modified residue. In some embodiments, the nucleic acid includes 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more. 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29or more, 30 or more chemically modified residues. Tn some embodiments, the nucleic acid includes 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, 1-13, 1-14, 1-15, 1-20, 1-25, or 1-30 chemically modified residues. In some embodiments, the nucleic acid includes 1-10 chemically modified residues. In some embodiments, the nucleic acid includes 8 chemically modified residues. In some embodiments, the nucleic acid includes 6 chemically modified residues.

[0102] The chemically modified residues can be distributed along the isolated nucleic acid in any suitable manner. In some embodiments, a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue. In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleic acid, e.g., the 5’ half of the nucleic acid. In some embodiments, the nucleic acid includes at least one chemically modified residue within the second half of the nucleic acid, e.g., the 3’ half of the nucleic acid. In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleic acid, e.g., the 5’ half of the nucleic acid, and at least one chemically modified residue within the second half of the nucleic acid, e.g., the 3’ half of the nucleic acid. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues from the 5’ end of the nucleic acid. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues from the 3’ end of the nucleic acid. In some embodiments, no two chemically modified residues are adjacent each other in the nucleic acid. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5. 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 5’ end of the nucleic acid. In some embodiments, the nucleic acid includes 1, 1. 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7. 8, 9, 10 residues, respectively, from the 3’ end of the nucleic acid. In some embodiments, the nucleic acid includes the same number of chemically modified residues in the 5’ half and 3’half of the nucleic acid. In some embodiments, the nucleic acid includes 3 chemically modified residues within 5 nucleotides from the 5’ end of the nucleic acid and / or 3 chemically modified residues within 5 residues from the 3’ end of the nucleic acid.

[0103] In some embodiments, the chemically modified residues are within the nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or sequence variant thereof. In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleobase sequence, e.g., the 5’ half of the nucleobase sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 1-13 of the nucleobase sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within the second half of the nucleobase sequence, e.g., the 3’ half of the nucleobase sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 14-26 of the nucleobase sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 1-13 of the nucleobase sequence, and at least one chemically modified residue within positions 14-26 of the nucleobase sequence. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7. 8, 9, 10 or more residues from the 5’ end of the nucleobase sequence. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5. 6, 7, 8, 9, 10 or more residues from the 3’ end of the nucleobase sequence. In some embodiments, no two chemically modified residues are adjacent to each other in the nucleobase sequence. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 5’ end of the nucleobase sequence. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 3’ end of the nucleobase sequence. In some embodiments, the nucleic acid includes the same number of chemically modified residues in the 5’ half and 3’ half of the nucleobase sequence. In some embodiments, the nucleic acid includes 3 chemically modified residues within 5 residues from the 5’ end of the nucleobase sequence and / or 3 chemically modified residues within 5 residues from the 3’ end of the nucleobase sequence. In some embodiments, the nucleic acid includes a different number of chemically modified residues in the 5’ half and 3’ half of the nucleobase sequence. In some embodiments, the nucleic acid includes a greater number of chemically modified residues in the 3’ half than in the 5’ half of the nucleobase sequence. In some embodiments, the nucleic acid includes 3 chemicallymodified residues within 5 residues from the 5’ end of the nucleobase sequence and / or 3, 4, or 5 chemically modified residues within 5 residues from the 3’ end of the nucleobase sequence.

[0104] In some embodiments, the isolated nucleic acid includes a chemically modified residue at one or more of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence (e.g., as numbered according to SEQ ID NO:2). In some embodiments, the isolated nucleic acid includes a chemically modified residue at one or more of positions 1, 3, 5, 23, 25, and 27 of the nucleobase sequence (e.g., as numbered according to SEQ ID NO:4). In some embodiments, the isolated nucleic acid includes a chemically modified residue at positions 1, 3, 5, 22, 24 and 26 of the nucleobase sequence (e.g., as numbered according to SEQ ID NO:2). In some embodiments, the isolated nucleic acid includes a chemically modified residue at positions 1, 3, 5, 23, 25 and 27 of the nucleobase sequence (e.g., as numbered according to SEQ ID NO:4). In some embodiments, the isolated nucleic acid has the nucleobase sequence CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or a sequence variant thereof, where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence are chemically modified residues. In some embodiments, the isolated nucleic acid has the nucleobase sequence CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO: 4), where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 23, 25, and 27 of the nucleobase sequence are chemically modified residues. In some embodiments, the isolated nucleic acid comprises the chemically modified residue at one or more of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence (e.g., one or more of the first, third and fifth residues from the 5’ end, and one or more of the first, third and fifth residues from the 3’ end). In some embodiments, the isolated nucleic acid comprises the chemically modified residue at the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence (e.g., at the first, third and fifth residues from the 5’ end, and at the first, third and fifth residues from the 3’ end). In some embodiments, the chemically modified residue(s) increases in vitro and / or in vivo stability of the nucleic acid, relative to a nucleic acid having the same nucleobase sequence where the residues are not chemically modified. In some embodiments, the chemically modified residue(s) increases therapeutic potency of the nucleic acid, e.g., for treating an inflammatory condition, cardiac injury, or sepsis, relative to a nucleic acid having the same nucleobase sequence where the residues are not chemically modified.

[0105] The isolated nucleic acid in some embodiments includes one type, or two or more different types of chemically modified residues. In some embodiments, the chemically modified residue has a methylene bridge connecting the 2’-0 atom and the 4’-C atom of the nucleotide sugar ring to lock the conformation (Locked Nucleic Acid (LNA)). In some embodiments, the isolated nucleic acid includes the nucleobase sequence CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or a sequence variant thereof, where the nucleic acid is RNA and one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid comprises a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO: 2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the nucleic acid is RNA, and where positions 1, 3. 5, 22, 24, and 26 of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid has the nucleobase sequence CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or has a variant nucleobase sequence at least 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, and where each of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence is a LNA. In some embodiments, the isolated nucleic acid is a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, and where each of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence is a LNA. In some embodiments, the isolated nucleic acid includes the nucleobase sequence CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO: 4), where the nucleic acid is RNA and one or more (e.g.. any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 23, 25, and 27 of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid has thenucleobase sequence CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO: 4), where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 23, 25, and 27 of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid includes the nucleobase sequence CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or a sequence variant thereof, where the nucleic acid is RNA and one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid comprises a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the nucleic acid is RNA, and where the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence are LNA. In some embodiments, the isolated nucleic acid includes a nucleobase sequence of CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, and where each of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence is a LNA.

[0106] The isolated nucleic acid, in some embodiments, can include any suitable chemical modification. In some embodiments, the chemical modification is a backbone modification, e.g., modification of the sugar / phosphate backbone. In some embodiments, the chemical modification is a backbone sugar modification. In some embodiments, the chemically modified residue includes a LNA. In some embodiments, the chemical modification includes the introduction of a phosphorothioate group as linker between residues. Suitable backbone modifications of the chemically modified residues include, without limitation, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. In some embodiments, the chemical modification is a base modification.

[0107] The nucleic acids of the present disclosure can be prepared using any suitable option. Suitable options include, without limitation, chemical synthesis, enzymatic production and / or biological production. In some embodiments, the nucleic acids are prepared using chemical synthesis. Any suitable option for chemical synthesis of nucleic acids can beused. Suitable options include, without limitation, phosphodiester, phosphotriester, phosphoramidite, phosphite-triester, and solid phase synthesis approaches. In some embodiments, preparing the nucleic acids includes in vitro transcription. In some embodiments, the nucleic acids are prepared using recombinant DNA technology. In some embodiments, the nucleic acids are prepared by chemically modifying an unmodified nucleic acid having a nucleobase sequence of interest.COMPOSITIONS

[0108] Also provided herein are compositions that include the isolated nucleic acid of the present disclosure. In some embodiments, the composition is a pharmaceutical composition. In some embodiments the composition includes pharmaceutically acceptable excipient. Some non-limiting examples of materials which can serve as pharmaceutically-acceptable excipients include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or poly anhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other nontoxic compatible substances employed in pharmaceutical formulations.

[0109] In some embodiments, the composition is a cell-free composition, e.g., the composition is substantially free of cells such as cardiosphere-derived cells (CDC). In some embodiments, the composition is an exosome-free composition, or an exosome-free composition. As used herein, “cell-free,” “exosome-free,” and “extracellular vesicle-free” denotes that no substantive amount of cells, exosome or extracellular vesicle, respectively is present. In some embodiments, no detectable amount of cells (or an amount below thedetection limit) is present in a cell-free composition. In some embodiments, no detectable amount (or an amount below the detection limit) of exosomes is present in an exosome-free composition. In some embodiments, no detectable amount (or an amount below the detection limit) of EV is present in an EV-free composition.

[0110] In some embodiments, the composition includes a transfection reagent, e.g., to promote delivery of the nucleic acid to a target cellular target ( vitro or in vivo). Any suitable transfection reagent can be included in the composition. Suitable transfection reagents include, without limitation, a liposome, extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, the lipid is a cationic lipid, as provided herein. In some embodiments, the transfection reagent includes DharmaFECT® or Lipofectamine®. In some embodiments, the nucleic acid of the present disclosure is formulated with the transfection reagent in the composition so as to promote cellular uptake and / or pharmacokinetics of the nucleic acid.

[0111] Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV), which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV), which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV), which may be between 50 and 500 nm in diameter. Liposome design may include, without limitation, opsonins or ligands in order to improve the attachment of liposomes to target tissue / cells, or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the cargo, e.g., a nucleic acid of the present disclosure.

[0112] In some embodiments, the composition includes, without limitation, liposomes such as those formed from l,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), l,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[l,3]-dioxolane (DLin-KC2-DMA), and MC3 and liposomes such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).

[0113] In some embodiments, the composition includes a cationic lipid. Any suitable cationic lipid may be used in the present compositions. Suitable cationic lipids include, without limitation, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. In some embodiments, the composition includes a cationic lipid complex, e.g., a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, the cationic lipid is PEGylated, e.g., 2 kDa PEG (“PEG2000”). Any suitable option can be used to PEGylate the cationic lipid. In some embodiments, PCLC is formed by exposing a mixture of PEG and the cationic lipid to one or more freeze / thaw cycles, e.g., 1, 2, 3, 4, 5 or more freeze / thaw cycles. In some embodiments, a freeze / thaw cycle includes freezing the mixture with liquid nitrogen (e.g., around -190 °C) for about 5 minutes, and thawing at about 60 °C for about 5 minutes. A nucleic acid of the present disclosure can be mixed with the PCLC to generate a complex of the nucleic acid and the PCLC.

[0114] In some embodiments, the composition includes extracellular vesicles (EV), e.g., exosomes. The extracellular vesicles (EV) can be those from any suitable source, e.g., EV derived from cardiosphere-derived cells (CDC), or from fibroblasts. Suitable EV, such as CDC-derived EV, are provided in, e.g., U.S. Application Publication Nos. 20080267921, 20160158291 and 20160160181; Smith et al„ Circulation. 2007. 115:896-908; Aminzadeh, M. A. et al. Stem Cell Reports 10, 942-955 (2018); and Ibrahim et al., Stem Cell Reports. 2014 May 8;2(5):606-19, Ibrahim, A. G. et al. Nanomedicine 33, 102347 (2020), each of which is incorporated by reference in its entirety. In some embodiments, the EVs are those isolated from serum-free media conditioned by human CDCs in culture. In some embodiments, the composition includes EV and liposomes and / or PCLC as transfection reagents. In some embodiments, the composition is substantially free of CDC-derived EV.

[0115] EVs, e.g., exosomes, disclosed herein can vary in size, depending on the embodiment. Depending on the embodiment, the size of the EVs ranges in diameter from about 15 nm to about 95 nm in diameter, including about 15 nm to about 20 nm, about 20 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about 50 nm to about 60 nm, about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 95 nm, and overlapping ranges thereof. In several embodiments, EVs are larger (e.g.. those ranging from about 140 to about 210 nm, including about 140 nm to about 150 nm, about 150 nm to about 160 run, about 160 nm to about 170 nm, about 170nm to about 180 nm, about 180 nm to about 190 nm, 190 nm to about 200 nm, about 200 nm to about 210 nm, and overlapping ranges thereof). In some embodiments, the EV diameter is in a range of about 15 nm to about 200 nm in diameter, including about 15 nm to about 20 nm, about 20 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about 50 nm to about 60 nm. about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 100 nm, about 100 nm to about 110 nm, about 110 nm to about 120 nm, about 120 nm to about 130 nm, about 130 nm to about 140 nm, about 140 nm to about 150 nm, about 150 nm to about 160 nm, about 160 nm to about 170 nm, about 170 nm to about 180 nm, about 180 nm to about 190 nm, about 190 nm to about 200 nm, and overlapping ranges thereof. In some embodiments, the EVs that are generated from the original cellular body are 100, 200, 300, 400, 500, 600, 700. 800, 900, 1,000, 2,000. 5,000, or 10,000 times smaller in at least one dimension (e.g., diameter) than the original cellular body.

[0116] The composition containing the EV and nucleic acid of the present disclosure can be prepared using any suitable option. In some embodiments, loading the nucleic acid into the EV includes: formulating the nucleic acid with liposomes and / or PCLC, e.g., as provided above, to generate a nucleic acid-liposome mixture; combining the nucleic acid-liposome mixture with the EV; and enriching for EV associated with exosome markers to generate a population of EV enriched for the nucleic acid. Combining the nucleic acidliposome mixture with the EV can be done using any suitable option. In some embodiments, the nucleic acid-liposome mixture is combined with the EV at 37 °C with shaking for about 30 minutes or more. Enriching to generate a population of EV enriched for the nucleic acid can be done using any suitable option. In some embodiments, enriching for EV associated with exosome markers includes immunoprecipitating EV associated with exosome markers using antibodies specific to an exosome marker. In some embodiments, the exosome marker is one or more of CD9. CD63 and CD81. In some embodiments, enriching for EV associated with exosome markers includes immunoprecipitating EV associated with all the exosome markers, CD9, CD63 and CD81. In some embodiments, the size distribution of the population of EV enriched for the nucleic acid is substantially unimodal. In some embodiments, at least 80%, 85%, 90%, 95%, 97%, 99% of the population has a diameter under a single peak in the size distribution. In some embodiments, the population of EV enriched for the nucleic acid has anaverage diameter of about 50-180 nm, e.g., 60-170 nm, 70-160 nm, 80-150 nm, 90-140 nm, 100-130 nm, or about 110-130 nm.

[0117] In some embodiments, the composition includes casein, e.g., a casein micelle. In some embodiments, the composition includes casein phosphoprotein. In some embodiments, the composition includes chitosan. In some embodiments, the composition includes casein and chitosan. In some embodiments, the composition includes a caseinchitosan complex. In some embodiments, the isolated nucleic acid in the composition is encapsulated in a casein-chitosan complex. In some embodiments, the composition includes one or more of phosphoproteins: alpha si casein, alpha s2 casein, beta casein, and kappa casein. In some embodiments, the composition includes two or more, three or more, or all four phosphoproteins: alpha si casein, alpha s2 casein, beta casein, and kappa casein. The phosphoproteins may be present in the composition at any suitable concentration (relative to each other, and relative to the total volume of the composition), and in some embodiments, is present in an amount suitable for forming casein micelles. In some embodiments, the casein phosphoproteins are collectively present in the composition at about 5-10 % (weight by volume). In some embodiments, the casein phosphoproteins are collectively present in the composition at about 8 % (weight by volume). The casein phosphoproteins can be those from any suitable animal, e.g., mammal such as, but not limited to, human, non-human primate, cow, pig, horse, camel, goat, and sheep. In some embodiments, the casein phosphoproteins are bovine alpha si casein, alpha s2 casein, beta casein, and kappa casein. Suitable casein formulations with EV are provided in, e.g., Aminzadeh et al., J Extracell Vesicles. 2021 Jan;10(3):el2045, the entirety of which is incorporated herein by reference. In some embodiments, a composition, e.g., pharmaceutical composition, of the present disclosure formulated with casein, as provided herein, is suitable for oral administration to the subject. Without being bound by theory, the casein phosphoproteins in the composition are thought to increase the bioavailability of orally administered EV and / or liposomes and their cargo, e.g., the nucleic acid of the present disclosure.

[0118] In several embodiments, a composition for enhancing the oral bioavailability of a therapeutic nucleic acid of the present disclosure comprises at least two phosphoproteins selected from alpha si casein, alpha s2 casein, beta casein, and kappa casein, where the phosphoproteins are present in an amount between about 5% to about 10% (weightby volume) of the composition, in a physiologically compatible excipient. Tn several embodiments, the composition includes the alpha si casein in an amount between about 0% to about 50% (e.g., about 10% to about 45%. about 20% to about 40%, about 25% to about 40%, about including 30% to about 40%) (by weight), the alpha s2 casein in an amount between about 0% to about 20% (e.g., about 5% to about 15%, about 7% to about 12%, including about 8% to about 12%) (by weight), the beta casein in an amount between about 0% to about 50% (e.g., about 10% to about 45%, about 20% to about 40%, about 25% to about 40%, about including 30% to about 40%) (by weight), and the kappa casein in an amount between about 0% to about 20% (e.g., about 5% to about 18%, about 8% to about 18%, including about 10% to about 15%) (by weight) of the phosphoprotein mass in the composition. The present compositions can provide for enhanced oral bioavailability of therapeutic nucleic acids, such as TY2.

[0119] In several embodiments, a composition for enhancing the oral bioavailability of a therapeutic nucleic acid of the present disclosure comprises at least two phosphoproteins selected from alpha si casein, alpha s2 casein, beta casein, and kappa casein, where the phosphoproteins are present in an amount between about 5% to about 10% (weight by volume) of the composition, in a physiologically compatible excipient. In several embodiments, the composition includes the alpha si casein in an amount between about 0% to about 50% (e.g., about 10% to about 45%, about 20% to about 40%, about 25% to about 40%, about including 30% to about 40%) (by weight), the alpha s2 casein in an amount between about 0% to about 20% (e.g., about 5% to about 15%, about 7% to about 12%, including about 8% to about 12%) (by weight), the beta casein in an amount between about 0% to about 50% (e.g., about 10% to about 45%, about 20% to about 40%, about 25% to about 40%, about including 30% to about 40%) (by weight), and the kappa casein in an amount between about 0% to about 20% (e.g., about 5% to about 18%. about 8% to about 18%, including about 10% to about 15%) (by weight) of the phosphoprotein mass in the composition. The present compositions can provide for enhanced oral bioavailability of therapeutic nucleic acids, such as TY2.

[0120] In several embodiments, the formulations provided for herein are in the form of lipid-bound vesicles, e.g., micelles or liposomes, and can therefore include any suitable number of particles. In some embodiments, the amount of micelles (e.g., casein-chitosancoated micelles) is in a range of about 106to about IO10particles, e.g., about 2 x 106to about IO10particles, about 5 xlO6to about IO10particles, about 107to about 5 x 109particles, about 2 xlO7to about 5 x 109particles, about 5 xlO7to about 5 x 109particles, including about 1 xlO8to about 2 x 109particles. In some embodiments, the amount of micelles (e.g., casein-chitin coated micelles) in the population is about 106, about 2 x 106, about 5 x 106, about 107, about 2 x 107. about 5 x 107. about 108. about 2 x 108. about 5 x 108. about 109. about 2 x 109. about 5 x 109, or about IO10particles, or an amount in between any two of the preceding values.

[0121] In several embodiments, the composition comprises casein-chitosan coated lipid micelles, where the casein phosphoproteins are present in the composition in suitable amounts (e.g., suitable total amount of phosphoprotein mass in the composition, suitable proportions of phosphoproteins relative to each other). In some embodiments, the composition includes two, three, or all four phosphoproteins selected from alpha si casein, alpha s2 casein, beta casein, and kappa casein. In some embodiments, the amount of a phosphoprotein in the composition depends on the amount of one or more other phosphoprotein present in the composition.

[0122] In some embodiments, alpha si casein is a phosphoprotein associated with the gene name CSN1S1. The alpha si casein can be a CSN1S1 phosphoprotein from any suitable mammal. In some embodiments, the alpha si casein is bovine (Gene ID: 282208), porcine (Gene ID: 445514), equine (Gene ID: 100033982), ovine (Gene ID: 443382), caprine (Gene ID: 100750242), cameline (Gene ID: 105090954), or human (Gene ID: 1446). In some embodiments, the alpha si casein is a non-human alpha si casein.

[0123] In some embodiments, the composition includes any suitable amount of alpha si casein. In some embodiments, the composition includes the alpha si casein in an amount, by weight, between about 0% to about 50%, e.g., between about 5% to about 50%, between about 10% to about 50%. between about 15% to about 45%, between about 20% to about 45%, including between about 25% to about 40%, of the phosphoprotein mass in the composition. In some embodiments, the composition includes the alpha si casein in an amount, by weight, of about 0%, 5%, 10%, 15%, 20%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, or an amount within a range defined by any two of the preceding values.

[0124] In some embodiments, the alpha s2 casein is a phosphoprotein associated with the gene name CSN1S2. The alpha s2 casein can be a CSN1S2 phosphoprotein from any suitable mammal. In some embodiments, the alpha s2 casein is bovine (Gene ID: 282209), porcine (Gene ID: 445515), equine (Gene ID: 100327035), ovine (Gene ID: 443383), caprine (Gene ID: 100861229), or cameline (Gene ID: 105090951).

[0125] The composition can include any suitable amount of alpha s2 casein. In some embodiments, the composition includes the alpha s2 casein in an amount, by weight, between about 0% to about 20%, e.g., between about 2% to about 18%, between about 3% to about 18%, between about 4% to about 17%, between about 5% to about 16%, including between about 5% to about 15%, of the phosphoprotein mass in the composition. In some embodiments, the composition includes the alpha s2 casein in an amount, by weight, of about 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 18%, 20%, or an amount within a range defined by any two of the preceding values.

[0126] In some embodiments, the beta casein is a phosphoprotein associated with the gene name CSN2. The beta casein can be a CSN2 phosphoprotein from any suitable mammal. In some embodiments, the beta casein is bovine (Gene ID: 281099), porcine (Gene ID: 404088), equine (Gene ID: 100033903), ovine (Gene ID: 443391), caprine (Gene ID: 100860784), cameline (Gene ID: 105080412), or human (Gene ID: 1447). In some embodiments, the beta casein is a non-human beta casein.

[0127] The composition can include any suitable amount of beta casein. In some embodiments, the composition includes the beta casein in an amount, by weight, between about 0% to about 50%, e.g., between about 5% to about 50%, between about 10% to about 50%, between about 15% to about 45%, between about 20% to about 45%, including between about 25% to about 40%, of the phosphoprotein mass in the composition. In some embodiments, the composition includes the beta casein in an amount, by weight, of about 0%, 5%, 10%. 15%, 20%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, or an amount within a range defined by any two of the preceding values.

[0128] In some embodiments, the kappa casein is a phosphoprotein associated with the gene name CSN3. The beta casein can be a CSN3 phosphoprotein from any suitable mammal. In some embodiments, the kappa casein is bovine (Gene ID: 281728), porcine (Gene ID: 445511), equine (Gene ID: 100033983), ovine (Gene ID: 443394), caprine (Gene ID:100861231), cameline (Gene IDs: 105080408 or 105090949), or human (Gene ID: 1448). In some embodiments, the kappa casein is a non-human kappa casein.

[0129] The composition can include any suitable amount of kappa casein. In some embodiments, the composition includes the kappa casein in an amount, by weight, between about 0% to about 20%, e.g., between about 2% to about 18%, between about 3% to about 18%, between about 4% to about 17%, between about 5% to about 16%, including between about 5% to about 15%, of the phosphoprotein mass in the composition. In some embodiments, the composition includes the kappa casein in an amount, by weight, of about 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 18%, 20%, or an amount within a range defined by any two of the preceding values.

[0130] Combinations of caseins from different species are used, in some embodiments. For example, in several embodiments, one or more human casein is used in combination with one or more bovine casein. Ratios of caseins are used in some embodiments, for example a 3: 1:3:1 ratio of alpha SI casei alpha s2 casei beta casei kappa casein. Different ratios may be used in some embodiments, for example 4: 1:4:1, 2: 1:2:1, or 1:1: 1:1. Ratios may also be used between any two given caseins in a composition, ranging from 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 1:5, 1:4, 1:3, 1:2, etc.

[0131] Any suitable total amount of the phosphoproteins may be present in the composition. In some embodiments, the phosphoproteins are present in an amount between 5% to about 10%, e.g., about 6% to about 10%, about 6% to about 9%, including about 6% to about 8%, (weight by volume) of the composition. In some embodiments, the phosphoproteins are present in an amount of about 5%, 6%, 7%, 8%. 9%, 10%. or an amount within a range defined by any two of the preceding values, (weight by volume) of the composition.

[0132] In some embodiments, one or more of the casein phosphoproteins are non-human casein phosphoproteins. In some embodiments, the exosomes and at least one of the casein phosphoproteins are from different species. In some embodiments, the exosomes are human exosomes, and one or more of the casein phosphoproteins are non-human casein phosphoproteins. In some embodiments, the exosomes are human exosomes, and one or more of the casein phosphoproteins are bovine (or ovine, porcine, caprine, cameline, or equine) casein phosphoproteins.

[0133] In some embodiments, the composition includes micellar structures formed by at least a portion of the casein phosphoproteins. In some embodiments, the casein micelles are substantially spherical. In some embodiments, a casein micelle in the composition has an average diameter (as measured per micelle) of about 40 nm, about 50 nm, about 60 nm, about 70 nm, about80 nm, about 90 nm, about 100 nm, about 110 nm, about 120 nm, about 130 nm, about 150 nm, about 200 nm, about 250 nm, about 300 nm, about 350 nm, about 400 nm, about 450 nm, about 500 nm or more, or an average diameter within a range defined by any two of the preceding values. In some embodiments, a casein micelle in the composition has an average diameter (as measured per micelle) in a range from about 40 nm to about 500 nm, e.g., from about 40 nm to about 400 nm, from about 50 nm to about 300 nm, from about 60 nm to about 250 nm, from about 70 nm to about 250 nm, from about 80 nm to about 200 nm, including from about 90 nm to about 150 nm. The casein micelles of the present composition are generally not precipitated or in gel form.

[0134] In some embodiments, the composition includes one or more colloidal minerals (e.g., minerals in suspension). In several embodiments, a complex (e.g., two or more) minerals are used as a colloidal mineral complex. The colloidal mineral complex can include any suitable mineral compounds and / or their salts. In some embodiments, the colloidal mineral complex includes, without limitation, one or more of calcium, magnesium, inorganic phosphate, citrate, sodium, potassium, and chloride, or their respective salts. In some embodiments, the colloidal mineral complex is present in an amount between about 2% and about 15%, e.g., about 2% to about 12%, about 5% to about 10%, about 5% to about 9%, including about 6% to about 9% (by weight) of the phosphoprotein mass in the composition. In some embodiments, the colloidal mineral complex is present in an amount of about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% or an amount within a range defined by any two of the preceding percentages.

[0135] In some embodiments, the composition is in a parenteral dose form. In some embodiments, the parenteral dosage form is sterile or capable of being sterilized before administering to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. In addition, controlled-release parenteral dosage forms can be prepared foradmini strati on to a subject. Suitable excipients that can be used to provide parenteral dosage forms of the nucleic acid include, without limitation: sterile water; water for injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to. sodium chloride injection, Ringer's injection, dextrose Injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as. but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0136] Also provided herein is a macrophage that includes a nucleic acid of the present disclosure. In some embodiments, the macrophage is a human macrophage. In some embodiments, the macrophage is a bone marrow-derived macrophage (BMDM). In some embodiments, a macrophage that has been exposed to the nucleic acid increases antiinflammatory activity compared to a suitable control, e.g., a macrophage that has not been exposed to the nucleic acid, or a macrophage that has been exposed to a control nucleic acid. In some embodiments, a macrophage that has the isolated nucleic acid has increased cytoprotective activity compared to a macrophage without the isolated nucleic acid. In some embodiments, the cytoprotective activity comprises efferocytosis and / or phagocytosis. In some embodiments, a macrophage that has the isolated nucleic acid has, has about, or has at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.2, 2.4. 2.6, 2.8, 3, 3.2, 3.5, 4, 4.5, 5, 6, 7. 8, 9, 10 fold or more increase in efferocytosis and / or phagocytosis compared to a suitable control (e.g., a macrophage that does not have the isolated nucleic acid), or optionally, efferocytosis and / or phagocytosis is increased by a fold amount in a range defined by any two of the preceding values (e.g., 1.2-10 fold, 1.5-8 fold, 2-5 fold, 2-4 fold, 2.2-3.5 fold, etc.). The amount of efferocytosis and / or phagocytosis can be measured using any suitable option, e.g., using an in vitro assay using fluorescently labeled bacteria (phagocytosis) or fluorescently labeled dead cardiomyocytes (efferocytosis), etc. In some embodiments, a macrophage that has the isolated nucleic acid shows enhanced survival, proliferation, and / or migration compared to a macrophage without the isolated nucleic acid. In some embodiments, the macrophage is in culture. In some embodiments, the macrophage is in a subject, e.g., in peripheral blood, bone marrow, and / or at a site of tissue injury.

[0137] In some embodiments, the isolated nucleic acid or composition thereof provided herein is for treatment of a heart condition or symptom thereof in a subject in need thereof. In some embodiments, the heart condition comprises myocardial infarction (MI). In some embodiments, the isolated nucleic acid or composition thereof is for treatment of an inflammatory and / or fibrotic condition in a subject in need thereof. In some embodiments, the isolated nucleic acid or composition thereof is provided for the treatment of an inflammatory condition comprises sepsis and / or symptom or sequelae thereof. In some embodiments, the fibrotic condition comprises cardiac fibrosis. In some embodiments, the fibrotic condition comprises pulmonary fibrosis. In some embodiments, the fibrotic condition includes myocardial infarction. In some embodiments, the fibrotic condition includes ACM.METHODS

[0138] Provided herein are methods of treating a subject in need thereof using the engineered nucleic acids of the present disclosure (also referred to herein as “treatment methods”). Conditions that may be treated by the treatment methods include, without limitation, heart conditions, inflammatory conditions, fibrotic conditions, and infections. In some embodiments, the engineered nucleic acids of the present disclosure are effective to treat conditions requiring tissue repair and / or regeneration, e.g., tissue injury due to inflammation. In some embodiments, the condition includes injury or damage to muscle (e.g., heart muscle) or lung tissue. In some embodiments, the conditions include, without limitation, heart failure, muscular disorders, myocardial infarction (MI), cardiac disorders, myocardial alterations, muscular dystrophy, fibrotic disease, inflammatory disease, viral infection, sepsis, or wound healing. In some embodiments, the conditions treated by the present treatment methods are a symptom and / or sequelae of an infection. In some embodiments, the infection comprises sepsis. In some embodiments, the heart condition includes myocardial infarction. In some embodiments, the heat condition includes ischemic cardiac muscle injury. In some embodiments, ischemic cardiac muscle injury comprises damage to cardiac muscle due to ischemia. In some embodiments, ischemic cardiac muscle injury includes ischemic / reperfusion injury, e.g., damage to cardiac muscle from reperfusion following ischemia. In some embodiments, ischemic cardiac muscle injury includes cardiac muscle fibrosis. In some embodiments, the fibrotic condition includes myocardial infarction. In some embodiments, the fibrotic condition includes ACM.

[0139] In some embodiments, conditions treated by the treatment methods include, without limitation, conditions associated with an inflammatory condition. In some embodiments, a subject being administered the isolated nucleic acid of the present disclosure, according to the treatment methods herein, is in need of treatment for conditions associated with an inflammatory condition. The conditions associated with inflammation can include, without limitation, inflammation of the heart. In some embodiments, the conditions treated by the present treatment methods are a symptom and / or sequelae of a cardiac injury. In some embodiments, the method includes identifying a subject having or diagnosed with a heart condition or inflammatory condition, as described herein, and administering a therapeutically effective amount of the nucleic acids of the present disclosure to the subject.

[0140] In some embodiments, a treatment method includes a method of treating a heart condition or symptom thereof, the method including administering to a subject in need of treating a heart condition or symptom thereof a therapeutically effective amount of the nucleic acid (or the composition containing the nucleic acid) of the present disclosure. In some embodiments, the method includes identifying a subject having or diagnosed with a heart condition or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject. In some embodiments, the method includes identifying a subject who is at risk of, or has suffered myocardial infarction, or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject. In some embodiments, the method includes identifying a subject who is at risk of. or has suffered heart failure, or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject. In some embodiments, the method includes identifying a subject who is at risk of, or has suffered cardiac injury, or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject.

[0141] A variety of heart conditions may be treated by the present methods. In some embodiments, the heart condition includes a symptom and / or sequelae of heart failure. In some embodiments, the heart condition includes myocardial infarction (MI).

[0142] In some embodiments, the subject is a subject who has or has suffered heart failure. In some embodiments, the subject is a subject who has or has suffered myocardial infarction. In some embodiments, the subject is a subject who has or has suffered acute myocardial infarction. In some embodiments, the subject is at risk of having heart failure and / or myocardial infarction (e.g., myocardial infarction).

[0143] In some embodiments, the subject is at risk of developing the heart condition. In some embodiments, the subject is at risk of developing the heart condition based on one or more of the subject’s family history, genetic predisposition, life style, and / or medical history. In some embodiments, the subject has one or more comorbidities for the heart condition. In some embodiments, the one or more comorbidities includes obesity and / or hypertension. In some embodiments, the subject has, or is diagnosed with, the heart condition.

[0144] Also provided is a method of treating an inflammatory or fibrotic condition or symptom thereof, the method including administering to a subject in need of treating an inflammatory or fibrotic condition or symptom thereof a therapeutically effective amount of the nucleic acid (or the composition containing the nucleic acid) of the present disclosure. In some embodiments, the method includes identifying a subject having or diagnosed with the inflammatory or fibrotic condition or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject. In some embodiments, the inflammatory condition comprises an infection and / or symptom or sequelae thereof. In some embodiments, the infection comprises sepsis. In some embodiments, the symptom or sequelae of the infection comprises heart and / or lung dysfunction. In some embodiments, the sepsis is caused by Pneumonia, a urinary tract infection (UTI), a kidney infection, a gastrointestinal infection (eg., appendicitis), a skin infection (e.g., cellulitis, a wound infection), and / or a bloodstream infection. In some embodiments, the sepsis is caused by Staphylococcus aureus (staph). In some embodiments, the sepsis is caused by E. coli. In some embodiments, the sepsis is caused by Streptococcus (strep). In some embodiments, the sepsis is caused by an antibiotic resistant strain of bacteria. In some embodiments, the sepsis is caused by a fungus, a parasite, and / or a viral infection. In some embodiments, the subject is over 65 years of age. In some embodiments, the subject is a new born / infant.

[0145] In some embodiments, a treatment method includes a method of treating sepsis or symptoms thereof, the method including administering to a subject in need of treating sepsis or symptom thereof a therapeutically effective amount of the nucleic acid (or the composition containing the nucleic acid) of the present disclosure. In some embodiments, the method includes identifying a subject having or diagnosed with sepsis or a symptom thereof, as described herein, and administering a therapeutically effective amount of the isolated nucleic acid of the present disclosure to the subject. In some embodiments, the isolated nucleic acid is co-administered with an antibiotic, an anti-fungal and / or an anti-parasitic agent.

[0146] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has one or more physiological dysfunction. In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has one or more of: elevated E / e’ ratio, cardiac hypertrophy, myocardial fibrosis, wasting, increased bacterial load in the heart and / or lungs, enlarged spleen, elevated cytokine levels in the heart and / or lungs, and elevated systemic inflammatory markers. In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject ameliorates one or more symptoms of the inflammatory or heart condition (e.g., reduced fibrosis, infarct size, reduced circulating level of inflammatory cytokines, reduced circulating level of a marker for cardiac injury, increased cardiac function, etc.), compared to a reference level (e.g., a suitable control level of the symptom for the inflammatory condition). In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject ameliorates one or more symptoms of the inflammatory condition in a clinically meaningful manner.

[0147] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has one or more symptom of shivering, fever, feeling very cold, being in extreme pain or discomfort, being pale, discolored, or having clammy / sweaty skin, being sleepy, confused, or difficult to wake, and / or having shortness of breath.

[0148] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has an elevated E / e’ ratio, e.g., compared to a reference level (such as, without limitation, the subject’s E / e’ ratiobefore developing a heart condition, the subject’s E / e’ ratio before administering, or an average E / e’ ratio of a healthy individual). In some embodiments, the subject has an elevated E / e’ ratio, and administering the therapeutically effective amount of the nucleic acid (or composition thereof) reduces the E / e’ ratio. In some embodiments, the subject’s E / e’ ratio is reduced by, by about, or by at least 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%. 75%, 80%. 85%, 90% or more, or by a percentage in a range defined by any two of the preceding values (e.g., 5-90%, 10-80%, 15-75%, 20-85%, 30-70%, 40-85%, etc.), after administering the therapeutically effective amount of the nucleic acid (or composition thereof). In some embodiments, the subject’s E / e’ ratio is reduced at least to a level that is deemed no longer to be clinically relevant after administering the therapeutically effective amount of the nucleic acid (or composition thereof).

[0149] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has a reduced ejection fraction percentage, e.g.. compared to a reference level (such as, without limitation, the subject’s ejection fraction percentage before developing a heart condition, or an average ejection fraction percentage of a healthy individual). In some embodiments, the subject has an ejection fraction percentage, and administering the therapeutically effective amount of the nucleic acid (or composition thereof) increases the ejection fraction percentage. In some embodiments, the subject’s ejection fraction percentage is increased by, by about, or by at least 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more, or by a percentage in a range defined by any two of the preceding values (e.g., 5-90%. 10-80%. 15-75%, 20-85%, 30-70%, 40-85%, etc.), after administering the therapeutically effective amount of the nucleic acid (or composition thereof). In some embodiments, the subject’s ejection fraction percentage is increased at least to a level that is deemed no longer to be clinically relevant after administering the therapeutically effective amount of the nucleic acid (or composition thereof).

[0150] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has an increase in QRS duration, QT duration, and / or QT (measured in milliseconds (ms) by electrocardiogram (ECG), e.g., compared to a reference level (such as, without limitation, the subject’s QRS duration, QT duration, and / or QTc before administering, or an average of the values from of a healthyindividual). In some embodiments, the subject has long QRS durations, QT durations, and / or long QTs and administering the therapeutically effective amount of the nucleic acid (or composition thereof) reduces QRS duration, QT duration, and / or QTc. In some embodiments, the QRS duration, QT duration, and / or QTc of the subject are reduced by, by about, or by at least 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%. 75%, 80%, 85%, 90% or more, or by a percentage in a range defined by any two of the preceding values (e.g., 5-90%, 10-80%, 15-75%, 20-85%, 30-70%, 40-85%, etc.), after administering the therapeutically effective amount of the nucleic acid (or composition thereof). In some embodiments, the subject’s QRS duration, QT duration, and / or QTc are reduced at least to a level that is deemed no longer to be clinically relevant after administering the therapeutically effective amount of the nucleic acid (or composition thereof).

[0151] In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject reduces infarct size by, by about, or by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95% or more, or optionally it is reduced by a percentage in a range defined by any two of the preceding values (e.g., 10-95%, 15-50%, 20-60%, 30-45%, 40-75%, 50-90%, etc.), compared to a reference size (e.g., a suitable control infarct size, such as the infarct size in the subject before administering the isolated nucleic acid). In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject reduces circulating level of a marker for cardiac injury (e.g., cTnl) by, by about, or by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95% or more, or optionally it is reduced by a percentage in a range defined by any two of the preceding values (e.g., 10-95%. 15-50%, 20-60%, 30-45%, 40-75%, 50-90%, etc.), compared to a reference level (e.g., a suitable control level, such as the level in the subject before administering the isolated nucleic acid).

[0152] In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject reduces circulating level of a marker for hepatic dysfunction (e.g., alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, albumin, and / or prothrombin time (PT / INR)) or hypoperfusion (e.g., serum lactate) by, by about, or by at least 10, 15, 20, 25, 30. 35, 40, 45, 50, 55, 60, 65, 70, 75. 80, 85, 95% or more, or optionally it is reduced by a percentage in a range defined by any two of the preceding values (e.g., 10-95%,15-50%, 20-60%, 30-45%, 40-75%, 50-90%, etc.), compared to a reference level (e.g., a suitable control level, such as the level in the subject before administering the isolated nucleic acid).

[0153] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has elevated level of one or more cytokines, e.g., inflammation-related cytokines. In some embodiments, the subject has elevated circulating levels of the one or more cytokines. In some embodiments, the subject has elevated level of one or more cytokines in the heart and / or lungs. In some embodiments, the one or more cytokines include one or more of: IL-6. TNF, IL-10 and IL-lb. In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject reduces the cytokine level by, by about or by at least 5, 7.5, 10, 12.5, 15%, 17.5, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90% or more, compared to a reference level (e.g., the cytokine level before the administering), optionally the cytokine level is reduced by a percentage in a range defined by any two of the preceding values (e.g.. 5-90%, 10-80%, 15-75%, 20-85%, 30-70%, 40-85%, etc.).

[0154] In some embodiments, before administering the therapeutically effective amount of the isolated nucleic acid or composition thereof, the subject has elevated level of one or more of the following fibrotic marker genes in cardiac tissue: Collal, Col3al, Ctgf, Tgf-f). Postn, Mfap4, and Fnl. In some embodiments, administering the therapeutically effective amount of the isolated nucleic acid to the subject reduces fibrotic gene expression levels by, by about, or by at least 5, 7.5, 10, 12.5, 15%, 17.5, 20, 25, 30, 35, 40, 45. 50, 55, 60, 65, 70, 75, 80, 85, 90% or more, compared to a reference level (e.g., the gene expression level before the administering), optionally the gene expression level is reduced by a percentage in a range defined by any two of the preceding values (e.g., 5-90%. 10-80%, 15-75%, 20-85%, 30-70%, 40-85%, etc.).

[0155] In some embodiments, any of the therapeutic effects of administering the therapeutically effective amount of the nucleic acid (or composition thereof) herein is sustained over the duration of treatment and is sustained across multiple doses of administration. In some embodiments, any of the therapeutic effects of administering the therapeutically effective amount of the nucleic acid (or composition thereof) herein is not transient over the duration of treatment.-M-

[0156] In some embodiments, a treatment method of the present disclosure treats any one or more of a variety of inflammatory conditions. In some embodiments, the inflammatory condition is a chronic condition. In some embodiments, the inflammatory condition comprises immunosuppression subsequent to a hyperinflammatory response. In some embodiments, the inflammatory condition includes an autoimmune disease, graft- versus-host disease (GVHD) or an immune response to an organ transplant. In some embodiments, the inflammatory condition includes viral infection, sepsis, arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis), multiple sclerosis, pemphigus, and type 1 diabetes (also referred to as insulin-dependent diabetes mellitus (IDDM)). In some embodiments, the inflammatory condition includes Behcet's disease, polymyositis / dermatomyositis, autoimmune cytopenias, autoimmune myocarditis, primary liver cirrhosis, Goodpasture's syndrome, autoimmune meningitis, Sjogren’s syndrome, systemic lupus erythematosus, Addison's disease, alopecia greata, ankylosing spondylitis, autoimmune hepatitis, autoimmune mumps, Crohn's disease, insulin-dependent diabetes mellitus, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroma, spondyloarthropathy, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia and ulcerative colitis. In some embodiments, the inflammation is related to a bone marrow transplantation. In some embodiments, the inflammation is related to allograft rejection following tissue transplantation. In some embodiments, the condition associated with inflammation (or inflammatory condition) comprises a symptom and / or sequelae of myocardial infarction, or heart failure. In some embodiments, the inflammatory condition comprises a cardiac inflammatory condition. In some embodiments, the condition associated with inflammation (or inflammatory condition) comprises inflammation and / or fibrosis of the heart. In some embodiments, the condition associated with inflammation (or inflammatory condition) is a symptom and / or sequelae of myocardial infarction or heart failure (e.g., reduced heart function, cardiac tissue fibrosis, etc.). In some embodiments the hyperinflammatory response is due to a cytokine storm or the activation of multiple inflammatory pathways.

[0157] In some embodiments, a treatment method of the present disclosure treats any one or more of a variety of fibrotic conditions. In some embodiments, the fibroticcondition is a cardiac fibrotic condition. Tn some embodiments, the cardiac fibrotic condition is arrhythmogenic cardiomyopathy (ACM). In some embodiments, the fibrotic condition is pulmonary fibrosis. In some embodiments, the fibrotic condition is one that is responsive to administration of the isolated nucleic acid.

[0158] In some embodiments, a treatment method of the present disclosure treats any one or more of a variety of cardiac arrhythmia conditions. In some embodiments, the cardiac arrhythmia condition is arrhythmogenic cardiomyopathy (ACM). In some embodiments, the cardiac arrhythmia condition is atrial fibrillation (AFib), bradycardia, tachycardia, or premature ventricular contractions (PVCs). In some embodiments, the subject experiences palpitations, dizziness or lightheadedness, fainting, shortness of breath, chest discomfort and / or fatigue or weakness. In some embodiments, the arrhythmia is caused by a heart condition including coronary artery disease, high blood pressure, heart attack and / or heart failure. In some embodiments, the arrhythmia condition is one that is responsive to administration of the isolated nucleic acid. In some embodiments, the arrhythmia is caused by a lifestyle choice including stress, excessive alcohol, smoking, and / or excessive caffeine consumption. In some embodiments, the arrhythmia is caused by a genetic condition including Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Short QT Syndrome (SQTS), Progressive Cardiac Conduction Disease (PCCD), Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC / D), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM). In some embodiments, the subject is genetically predisposed to having or developing cardiac arrhythmia (e.g., ACM). In some embodiments, the subject is diagnosed as having an inherited condition that causes cardiac arrhythmia (e.g., ACM) by genetic testing. In some embodiments, the cardiac arrhythmia (e.g., ACM) or risk thereof is associated with a mutation in phospholamban (PLN), desmoplakin (DSP) or desmoglein 2 (DSG2). In some embodiments, the cardiac arrhythmia (e.g., ACM) or risk thereof is associated with a mutation in one or more desmosomal genes.

[0159] In some embodiments, administering the isolated nucleic acid decreases Pickl and / or IL6 expression in macrophages. In some embodiments, the isolated nucleic acid decreases Pickl and / or IL6 expression in macrophages, as detected by qPCR, histochemistry, microarray, and / or high throughput sequencing, by, by about, or by at least 10, 15, 20, 25, 30,35, 40, 45, 50, 60, or 70% or more compared to a suitable reference (e.g., the level of gene expression in macrophages before the subject received treatment).

[0160] In some embodiments, the subject is a human subject. In some embodiments, the subject is a non-human subject, e.g., a non-human mammal.

[0161] The isolated nucleic acid can be administered to the subject at any suitable therapeutically effective amount. In some embodiments, the therapeutically effective amount of the isolated nucleic acid includes, includes about, or includes at least 0.01 pg, 0.02 pg, 0.05 pg, 0.1 pg, 0.2 pg, 0.5 pg, 1 pg, 2 pg, 3 pg. 4 pg, 5 pg, 6 pg, 7 pg, 8 pg, 9 pg, 10 pg, 15 pg, 20 pg, 25 pg, 30 pg, 40 pg, 50 pg, 75 pg, 100 pg, 125 pg, 150 pg, 175 pg, 200 pg, 250 pg, 300 pg, 400 pg, 500 pg, 600 pg, 700 pg, 800 pg, 900 pg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 75 mg, 100 mg or more, or optionally, it includes an amount in a range defined by any two of the preceding values (e.g., 0.01 pg-0.1 pg, 0.1 pg-1 pg, 1 pg-10 pg, 10 pg-100 pg, 100 pg-1 mg, 1 mg-10 mg, 10 mg-100 mg). In some embodiments, the therapeutically effective amount is a weight-normalized amount. In some embodiments, the therapeutically effective amount of the isolated nucleic acid includes, includes about, or includes at least 0.001 pg / g, 0.002 pg / g, 0.005 pg / g. 0.01 pg / g, 0.02 pg / g, 0.05 pg / g, 0.1 pg / g, 0.15 pg / g, 0.2 pg / g, 0.5 pg / g, 1 pg / g, 2 pg / g, 3 pg / g, 4 pg / g, 5 pg / g, 6 pg / g, 7 pg / g, 8 pg / g, 9 pg / g, 10 pg / g, 15 pg / g, 20 pg / g, 25 pg / g, 30 pg / g, 35 pg / g, 40 pg / g, 45 pg / g, 50 pg / g, 60 pg / g, 70 pg / g, 80 pg / g, 90 pg / g, 100 pg / g of body weight, or more, or optionally, it includes an amount in a range defined by any two of the preceding values (e.g., 0.001 pg / g-0.01 pg / g, 0.01 pg / g-0.1 pg / g, 0.1 pg / g-1 pg / g, 1 pg / g-10 pg / g, 10 pg / g-100 pg / g). In some embodiments, the therapeutically effective amount of the isolated nucleic acid includes, includes about, or includes at least 0.001 mg / kg, 0.002 mg / kg, 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg of body weight, or more, or optionally, it includes an amount in a range defined by any two of the preceding values (e.g., 0.001 mg / kg-0.01 mg / kg, 0.01 mg / kg-0.1 mg / kg, 0.1 mg / kg-1 mg / kg, 1 mg / kg-10 mg / kg, 10 mg / kg-100 mg / kg). In some embodiments, the therapeutically effective amount of the isolated nucleic acid is, is about, or is at least 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500,1000 nM or more, or optionally, it is an amount in a range defined by any two of the preceding values (e.g., 0.01-1000 nM, 0.1-100nM, 1-100 nM, 20-80 nM, 0.5-150 nM, etc.). In some embodiments, the therapeutically effective amount of the isolated nucleic acid is, is about, or is at least 40 nM. In some embodiments, the therapeutically effective amount of the isolated nucleic acid is, is about, or is at least 80 nM. In some embodiments, the therapeutically effective amount of the isolated nucleic acid is in a range of 1-100 nM.

[0162] The isolated nucleic acid or composition can be administered to the subject at any suitable dosing schedule. In some embodiments, the therapeutically effective amount of the isolated nucleic acid or the composition is administered to the subject no more frequently than three time a week, twice a week, once a week (QW), once every two weeks (Q2W), once every month (QM), once every two months (Q2M), once every three months (Q3M), once every four months (Q4M) or longer, or at a frequency in a range defined by any two of the preceding values (e.g., three times a week to once every four months (Q4M), twice a week to once every two months (Q2M), or twice a week to once a month (QM)). In some embodiments, the nucleic acid is administered to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more times, or a number of times in a range defined by any two of the preceding values (e.g., 1-30 times, 2-20 times, 5-15 times, 1-20 times, etc.). In some embodiments, the isolated nucleic acid is administered to the subject at regular intervals. In some embodiments, the isolated nucleic acid is administered to the subject chronically.

[0163] The nucleic acid or composition can be administered using any suitable route of administration. Administration can be local or systemic. In some embodiments, administration is parenteral. Suitable options for administration include, without limitation, intravenous, intramuscular, subcutaneous, intra-arterial, intraperitoneal, intracardially, or oral administration. In some embodiments, the isolated nucleic acid or composition is administered orally. In some embodiments, the isolated nucleic acid or composition is administered by oral gavage. In some embodiments, the nucleic acid or composition is administered intravenously. In some embodiments, the nucleic acid or composition is administered by infusion.

[0164] In any treatment method described herein, in some embodiments, the method is an exosome-free method. In some embodiments, the method is an extracellular vesicle-free method. As used herein, “exosome-free” and “extracellular vesicle-free” denotes that no substantive amount of exosome or extracellular vesicle is involved. In someembodiments, a method or composition that is exosome-free may involve a composition or use thereof that is substantially or essentially free of exosomes. In some embodiments, a method or composition that is exosome-free may involve a composition or use thereof that is free of exosomes. In some embodiments, a method or composition that is exosome-free may involve a composition or use thereof that is substantially or essentially free of extracellular vesicles. In some embodiments, a method or composition that is exosome-free may involve a composition or use thereof that is free of extracellular vesicles. In some embodiments, the method is a cell-free method.

[0165] Also provided herein is a method immunomodulation (also referred to herein as immunomodulation methods). The method generally includes contacting an effective amount of the isolated nucleic acid or the composition of the present disclosure with a population of macrophages, to thereby modulate an anti-inflammatory activity of macrophages of the population. In some embodiments, the contacting is done in vitro. In some embodiments, the contacting includes contacting the effective amount of the isolated nucleic acid or the composition thereof with a population of macrophages ex vivo. In some embodiments, the contacting is done in vivo. In some embodiments, the contacting comprises administering to a subject in need of treating an inflammatory condition the effective amount of the isolated nucleic acid or the composition, to thereby modulate an anti-inflammatory activity of macrophages in the subject. In some embodiments, the nucleic acid induces changes in gene expression and / or epigenetic changes in macrophages that are exposed to the nucleic acids. In some embodiments, the contacting comprises administering to a subject in need of treating an inflammatory condition the effective amount of the isolated nucleic acid or the composition, to thereby modulate an anti-inflammatory activity of macrophages in the subject. In some embodiments, the macrophage is a human macrophage. In some embodiments, the subject is a human subject. In some embodiments, the subject is a non-human subject, e.g., a non-human mammal.

[0166] The population of macrophages can be contacted with the isolated nucleic acid or composition for any suitable amount of time. In some embodiments, the contacting is for 24 hours or more, 36 hours or more, 48 hours or more, 60 hours or more, 72 hours or more, or an amount of time in a range between any two of the preceding values.

[0167] Any suitable amount of nucleic acid can be contacted with the population of macrophages to promote the anti-inflammatory activity of the macrophages. In some embodiments, the effective amount depends on whether the contacting is done in vivo or in vitro. In some embodiments, any suitable amount of the isolated nucleic acid or composition thereof can be administered to the subject, e.g., as described hererin, to thereby contact the isolated nucleic acid with the population of macrophages in vivo.KITS

[0168] Also provided herein are kits that include the isolated nucleic acid (or a composition thereof) of the present disclosure. The present kit in some embodiments finds use in treating a heart condition, a fibrotic condition, infection, or an inflammatory condition, as provided herein. A kit can include the isolated nucleic acid (e.g., TY2), or a composition comprising the same, of the present disclosure. A kit can include the isolated nucleic acid of the present disclosure and a transfection reagent. In some embodiments, the transfection reagent comprises one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC). The transfections reagent can be any suitable transfection reagent, as provided herein. In some embodiments, the kit includes a pharmaceutically acceptable excipient, as provided herein. In some embodiments, the kit includes casein and / or chitosan. Kits can include one or more containers (e.g., vials, ampoules, test tubes, flasks or bottles) for holding one or more components of the kits. The kits may further include instructions for using the kit to treat a condition (e.g., MI or a symptom or sequelae thereof, sepsis, and / or inflammatory condition, etc.). The information and instructions may be in the form of words, pictures, or both, and the like.Additional Embodiments

[0169] Further non-limiting embodiments of the present disclosure are provided by the following numbered arrangements.1. An isolated nucleic acid comprising a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90% identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the isolated nucleic acid is RNA, wherein the isolated nucleic acid is at most 35 nucleobaseslong, optionally wherein the nucleobase sequence does not include or is not CCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:1).2. The isolated nucleic acid of Arrangement 1, wherein the nucleobase sequence comprises CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO:2), or wherein the nucleobase sequence comprises CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:4).3. The isolated nucleic acid of Arrangement 1 or 2, wherein the isolated nucleic acid comprises at least one chemically modified residue, optionally wherein a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue.4. The isolated nucleic acid of Arrangement 3, wherein the isolated nucleic acid comprises 1-10 chemically modified residues.5. The isolated nucleic acid of Arrangement 3 or 4, wherein the isolated nucleic acid comprises at least one chemically modified residue within the 5’ half of the nucleobase sequence and / or at least one chemically modified residue within the 3’ half of the nucleobase sequence.6. The isolated nucleic acid of any one of Arrangements 3-5, wherein the chemically modified residue comprises a backbone modification.7. The isolated nucleic acid of Arrangement 6, wherein the backbone modification comprises a backbone sugar modification, optionally wherein the chemically modified residue is a locked nucleic acid (LNA).8. The isolated nucleic acid of Arrangement 6 or 7, wherein the isolated nucleic acid comprises the chemically modified residue at one or more of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence, optionally wherein the nucleobase sequence comprises a LNA at the first, third and fifth residues from the 5’ end and the 3’ end.9. The isolated nucleic acid of Arrangement 6 or 7, wherein the nucleobase sequence comprises: CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein each of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence is a LNA.10. The isolated nucleic acid of any one of the preceding Arrangements, wherein the nucleic acid is 26 nucleobases long.11. An isolated nucleic acid comprising a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90% identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the nucleic acid is RNA.12. The isolated nucleic acid of Arrangement 11, wherein the nucleobase sequence is CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or wherein the nucleobase sequence comprises CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:4).13. The isolated nucleic acid of Arrangement 1 lor 12, wherein the isolated nucleic acid comprises at least one chemically modified residue, optionally wherein a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue.14. The isolated nucleic acid of Arrangement 13, wherein the isolated nucleic acid comprises 1-10 chemically modified residue.15. The isolated nucleic acid of any one of Arrangement s 13 or 14, wherein the isolated nucleic acid is at most 35 nucleobases long.16. An isolated nucleic acid consisting of a nucleobase sequence: CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, wherein each of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence is a LNA.17. A composition comprising:the isolated nucleic acid of any one of the preceding claims; anda pharmaceutically acceptable excipient.18. The composition of Arrangement 17, further comprising a transfection reagent.19. The composition of Arrangement 18, wherein the transfection reagent comprises one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC).20. The composition of Arrangement 17 or 18, wherein the transfection reagent comprises EV derived from cardiosphere-derived cells (CDC).21. The composition of any one of Arrangements 17-20, comprising a casein phosphoprotein.22. The composition of any one of Arrangements 17-21, comprising chitosan. 23. The composition of any one of Arrangements 17-22, wherein the isolated nucleic acid is encapsulated in a casein-chitosan complex.24. The composition of any one of Arrangements 17-23. comprising casein micelles.25. A macrophage comprising the isolated nucleic acid of any one of Arrangements 1-16, wherein a cytoprotective activity of the macrophage is increased compared to a macrophage without the isolated nucleic acid.26. The macrophage of Arrangement 25, wherein the macrophage is in a subject.27. The macrophage of Arrangement 25, wherein the macrophage is in culture. 28. The macrophage of any one of Arrangements 25-27, wherein the cytoprotective activity comprises efferocytosis and / or phagocytosis.29. A kit comprising:the nucleic acid of any one of Arrangements 1-16; anda transfection reagent.30. The kit of Arrangement 29, wherein the transfection reagent is one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG) -cationic lipid complex (PCLC).31. The kit of Arrangement 29 or 30, comprising: a casein phosphoprotein and / or chitosan.32. A method of treating a heart condition or symptom thereof, comprising administering to a subject in need of treating a heart condition or symptom thereof a therapeutically effective amount of the isolated nucleic acid of any one of Arrangements 1-16 or the composition of any one of Arrangements 17-24, thereby treating the heart condition or symptom thereof.33. The method of Arrangement 32, wherein the heart condition comprises a symptom and / or sequelae of heart failure.34. The method of Arrangement 32 or 33, wherein the heart condition comprises myocardial infarction (MI) or arrhythmogenic cardiomyopathy (ACM).35. The method of Arrangement 32, wherein the heart condition comprises a symptom or sequelae of an infection, optionally wherein the infection comprises sepsis.36. The method of any one of Arrangements 32-35, wherein the subject, before the administering, has one or more of: elevated E / e’ ratio, decreased ejection fraction, increased bacterial load in the heart and / or lungs, enlarged spleen, wasting, elevated serum lactate and / or aspartate transferase (AST) levels, increased frequency of ventricular arrhythmias, decreased cardiac conduction velocity, increased QRS, QT, QTc and / or action potential duration at 80% repolarization, and elevated cytokine levels in the heart and / or lungs.37. The method of any one of Arrangements 32-36, comprising identifying the subject in need of treating the heart condition or symptom thereof.38. A method of treating an inflammatory or fibrotic condition, comprising administering to a subject in need of treating an inflammatory or fibrotic condition a therapeutically effective amount of the nucleic acid of any one of Arrangements 1-16 or the composition of any one of Arrangements 17-24, thereby treating the inflammatory or fibrotic condition.39. The method of Arrangement 38, wherein the inflammatory condition comprises an infection and / or symptom or sequelae thereof, optionally wherein the infection comprises sepsis.40. The method of Arrangement 39, wherein the symptom or sequelae of the infection comprises heart and / or lung dysfunction.41. The method of any one of Arrangements 38-40, comprising identifying the subject in need of treating the inflammatory or fibrotic condition.42. The method of any one of Arrangements 38-41, wherein the inflammatory condition comprises immunosuppression subsequent to a hyperinflammatory response.43. The method of Arrangement 36. wherein the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.44. The method of any one of Arrangements 32-43, wherein the therapeutically effective amount of the isolated nucleic acid comprises from about 0.001 mg / kg to about 100 mg / kg, or 0.01-1000 nM.45. The method of any one of Arrangements 32-44, comprising administering the therapeutically effective amount of the isolated nucleic acid or the composition no more frequently than twice a week.46. The method of any one of Arrangements 32-45, comprising administering the therapeutically effective amount of the isolated nucleic acid or the composition intravenously, intramuscularly, intracardially, or orally.47. A method of immunomodulation, comprising contacting an effective amount of the isolated nucleic acid of any one of Arrangements 1-16, or the composition of any one of claims 17-24 with a population of macrophages, to thereby modulate an anti-inflammatory activity of macrophages of the population.48. The method of Arrangement 47, wherein the contacting comprises administering to a subject in need of treating an inflammatory condition the effective amount of the isolated nucleic acid or the composition, to thereby modulate an anti-inflammatory activity of macrophages in the subject.49. The method of Arrangement 47 or 48, wherein the macrophage is a human macrophage.50. The method of any one of Arrangements 47-49, wherein contacting the effective amount of the isolated nucleic acid or the composition with the population of macrophages reduces PICK1 expression in the macrophages, reduces IL6 expression in the macrophages, and / or increases macrophage phagocytosis.51. The isolated nucleic acid of any one of Arrangements 1-16 or the composition of any one of Arrangements 17-24 for treatment of a heart condition or symptom thereof in a subject in need thereof, optionally wherein the heart condition comprises myocardial infarction (MI) or arrhythmogenic cardiomyopathy (ACM).52. The isolated nucleic acid of any one of Arrangements 1-16 or the composition of any one of Arrangements 17-24 for treatment of an inflammatory and / or fibrotic condition in a subject in need thereof, optionally wherein the inflammatory condition comprises sepsis and / or symptom or sequelae thereof, or the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.

[0170] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting.EXAMPLESExample 1

[0171] This non-limiting example shows development of TY2.

[0172] yREX3 is a 26-nucleotide (nt) small non-coding RNA found in extracellular vesicles (EV) derived from cardiosphere-derived cells (CDC). yREX3 triggers profound transcriptomic effects in monocyte-derived macrophages compared to other cell types in the heart. Specifically, yREX3 silences Pickl expression through gene methylation (FIG. 1A). Pickl is an endocytic accessory protein involved in receptor recycling. Pickl suppression in macrophages leads to hyperphosphorylation of Smad3 and enhances their ability to clear dead cells, a process called efferocytosis. yREX3 is protective against myocardial infarction (MI). yREX3 exerts antifibrotic and anti-hypertrophic benefits comparable to those of CDC-EVs in a model of myocardial infarction (MI) induced by ischemia followed by reperfusion.

[0173] yREX3 effects on epigenomics and gene expression. FIG. 1A depicts a working hypothesis that yREX3 induces epigenetic modifications which alter gene expression in target cells. Epigenetic regulation refers to chromatin adaptations or DNA methylations which establish long-lasting gene expression patterns.

[0174] Modified mutant of yREX3 as lead candidate. While yREX3 is itself bioactive in several disease models, being chemically unmodified, it is potentially unstable and immunogenic. To bypass these limitations, several yREX3-inspired molecules were synthesized and screened in bone marrow-derived macrophages (BMDM) for their effect on Pickl expression. FIG. IB is a schematic of a two-step screening of yREX3-derived structural variants for optimization of activity. Step 1 was mutagenesis of the primary sequence and step 2 was the inclusion of locked nucleic acids (LNA). The candidate sequences generated and / or tested in Step 1 are listed in Table 1 below. Mutagenesis changes from wild type are both underlined and bolded. LNA residues are indicated with underlining and italics. As used herein, reference to “yREX3” denotes “yREX3WT” (e.g., SEQ ID NO:1 with no LNA) unless indicated otherwise.Table 1yREX3 and SEQID Sequencevariants NO: yREX3WTCCCCCCACUGCUAAAUUUGACUGGUU 1 yREX33’UtoACCCCCCACUGCUAAAUUUGACUGGUA 2 yREX35 CtoGGCCCCCACUGCUAAAUUUGACUGGUU 3 yREX35 7CCCCCCCCACUGCUAAAUUUGACUGGUU 4 TY2 (“UtoA”) CCCCCCACUGCUAAAUUUGACC / GGUA 5 CtoG GCCCCCACUGCUAAAUUUGACCGGW 7 7C CCCCCCCACUGCUAAAUUUGACI / GGUt / 8

[0175] Screening of yREX3 variants identified one (e.g., TY2) that exhibited bioactivity in the macrophage in vitro assay comparable to yREX3). Screening of yREX3 variants was performed in rat bone marrow derived macrophage (BMDM) exposed to the candidate RNAs (80nM) for 24 (FIG. 1C) and 48 hours (FIG. D) using pickl expression assays (n=3-4 biological replicates per group). TY2 had a U-to-A substitution of the 3’ nucleotide relative to yREX3, and further included LNA at the first, third, and fifth residues from the 5’ end and the 3’ end. Transfection of TY2 in BMDM decreased pickl expression in macrophages to a level comparable to silencing of pickl expression observed with yREX3 (FIGs. 1C-1D). The “7C” variant having seven Cs at the 5’ end (and alternating LNA at the first, third, and fifth residues from the 5’ end and the 3’ end) had an intermediate level of bioactivity in the pickl expression assay, and the “CtoG” variant having a substitution of guanosine for cytosine at the 5’ end (and alternating LNA at the first, third, and fifth residues from the 5’ end and the 3’ end) showed little bioactivity at 24 hours, and no bioactivity at 48 hours in the pickl expression assay. “Veh” indicates BMDM treated with vehicle, and “Scr” indicates BMDM treated with a control scrambled RNA. FIG. 2A schematically shows the naturally occurring, therapeutically bioactive small Y RNAs, yREX3. served as bioinspiration for structure-activity optimization studies to develop the lead candidate, TY2.

[0176] The stability of TY2 and yREX3 were tested in an RNase R protection assay (FIG. 2B). The results show that TY2 had increased stability compared to yREX3 when exposed to increasing concentrations of the exonuclease RNase R for 1 or 2 hours (FIG. 2B; n=3 biological replicates per group).Example 2

[0177] This non-limiting example shows the bioactivity of TY2 in an efferocytosis assay.

[0178] Therapeutic benefits ofTY2 in efferocytosis. TY2 improved the therapeutic effect of yREX3 in an efferocytosis assay (Fig. 3A-3B). Bone marrow derived macrophage (BMDM) exposed to Vehicle (Veh), yREx3, or TY2 were assayed for uptake of DiD-labeled dead rat cardiomyocytes in an efferocytosis assay (representative images taken at 48 hours, n=3 biological replicates / group; Fig, 3A). Compared to yREX3, TY2-exposed macrophages had increased capacity to take up dead rat cardiomyocytes as shown by the fold change (FC) to Veh (Fig. 3B).Example 3

[0179] This non-limiting example shows in vivo bioactivity of TY2 in a model of myocardial infarction (MI).

[0180] yREX3 and TY2 were formulated for oral administration (FIG. 4A). yREX3 or TY2 was first combined with a transfection reagent (e.g., liposome) to form a complex, which was then encapsulated in a casein-chitosan complex.

[0181] In vivo bioactivity. To assess disease-modifying bioactivity, the myocardial infarction (MI) model is used (FIG. 4B). Rats underwent MI, induced by 45 min of ischemia followed by reperfusion, and 20 minutes after reperfusion they received saline (Veh), yREX3 or TY2 orally by gavage. Forty-eight hours post-MI, both yREX3 and TY2 showed cardioprotective activity as shown by reduced scar mass measured by TTC staining (representative images; FIG. 4C) and infarct mass quantification (FIG. 4D) and lower circulating cardiac troponin I levels (cTnl; FIG.4E) compared to animals injected with vehicle or sham (n=3-7 animals / group, mean ± SEM).Example 4

[0182] This non-limiting example shows the therapeutic effect of TY2 in a model of sepsis.

[0183] Therapeutic benefits of TY2 in sepsis. Given the bioactivity of TY2 in a model of myocardial infarction (MI) (Example 3), the effect of TY2 in mice with sepsis was tested (FIG. 5A). Caecal ligation and puncture (CLP)-induced polymicrobial sepsis model was induced at day 0. Sham mice were submitted to the same procedures without caecal puncture. TY2 or vehicle were administered intravenously at day 1, 3 and 5 and mice sacrificed at day 7 for endpoint analyses.

[0184] Animals treated with TY2 showed improved survival compared to vehicle-treated animals (FIG. 5B). Both vehicle-treated and TY2-treated animals showed wasting at seven days after inducing sepsis, as measured by reduced body weight (FIG. 5C). Endpoint weights of organs (heart, lungs and spleen) normalized by tibia length showed that vehicle-treated and TY2-treated animals showed no effect on heart and lung weight (FIG. 5D). Sepsis induced an increase in spleen weight, and TY2 treatment reduced spleen weight to levels comparable to sham-treated animals.

[0185] The effect of TY2 on cardiac function in the sepsis model was determined. TY2 increased ejection fraction (EF) at day 7 compared to day 1 following CLP (FIG. 5E). TY2 also increased fractional shortening (FS) (FIG. 5F).

[0186] Ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity (E / E’) increased in CLP (FIG. 5G). E / E’ ratio decreased by day 7 in both vehicle- and TY2-treated animals. Left ventricular function was also assessed by measuring left ventricular internal dimension (LVID) (FIG. 5H). LVID decreased in TY2-treated CLP mice compared to vehicle-treated CLP mice.Example 5

[0187] This non-limiting example shows TY2 enhanced protection of the heart and lungs from sepsis.TY2 reduced bacterial 16S load.

[0188] Bacterial 16S load in heart and lung tissue from CLP or sham animals was used to estimate the quantity of bacterial DNA detected in the organ samples, as a measure for the severity of sepsis. As shown in Figure 51, TY2-treated CLP animals had decreased bacterial 16S load in heart samples compared to vehicle-treated CLP animals. Similarly, TY2-treated CLP animals had reduced bacterial 16S load in lung samples compared to vehicle-treated CLP animals (FIG. 5J).TY2 reduced inflammation-related cytokines in heart and lungs.

[0189] The level of cytokines in the heart or lungs of TY2-treated CLP mice was measured by qPCR at day 7. IL6, TNF, IL10 and ILlb increased in the heart after CLP induction, and TY2 treatment in CLP mice reduced the levels of these cytokines (FIG. 5K). In the lungs, ILlb expression increased after CLP induction, and TY2 treatment in CLP mice reduced the level of ILlb expression (FIG. 5L).

[0190] These results show that TY2 treatment can reduce bacterial load in the heart and lung due to sepsis, and reduce expression of inflammation-related cytokines that are upregulated in the heart and lung following sepsis.Example 7

[0191] This non-limiting example shows bioactivity of TY2 in macrophage phagocytosis.

[0192] To determine the effect of TY2 on phagocytosis by macrophages, an in vitro phagocytosis assay was performed, using bone marrow derived macrophages (BMDM). Macrophages treated with TY2 showed enhanced capacity to phagocyte se E. coli particles compared to vehicle-treated macrophages (FIGs. 5M and 5N). This result shows that TY2 increases the ability of macrophages to phagocytose E. coli.Example 8

[0193] This non-limiting example shows in vivo bioactivity of intravenously (IV) and orally administered TY2 in a model of myocardial infarction (MI) (FIG. 4B). This example relates to Example 3.

[0194] Therapeutic benefits of TY2 in MI. To compare disease-modifying bioactivity of IV- and orally-administered TY2, the model of myocardial infarction (MI) used in Example 3 (FIG.4B) was used. Forty-eight hours post-MI, both IV and orally administered yREX3 and TY2 showed cardioprotective activity as determined by TTC staining of heart tissue (FIG. 6A, representative images), reduced scar mass determined by infarct mass (FIG.6B), and lower circulating cardiac troponin I levels (cTnT; FIG. 6C) compared to animals injected with vehicle.Example 9

[0195] This non-limiting example shows the therapeutic effect of TY2 in a model of sepsis.

[0196] Therapeutic benefits of TY2 in sepsis. The therapeutic effects of TY2 in sepsis were further evaluated using the cecal ligation and puncture (CLP)-induced polymicrobial sepsis model (FIG. 5A) used in Example 4.

[0197] At 72 hours, a higher number of macrophages (marked by CD68) (FIG.7A) and more staining of phosphorylated Smad3 (pSmad3) (FIGs. 7A and 7B) were detected in heart sections from mice administered TY2 compared to vehicle-treated animals.

[0198] TY2 treatment also decreased serum lactate (FIG. 7C) and aspartate aminotransferase (AST) levels (a marker of hepatic dysfunction) (FIG. 7D) compared to vehicle-treated animals. Levels of glucose in the blood dropped in both TY2- and vehicle-treated mice compared to Sham (FIG.7E).Example 10

[0199] This non-limiting example shows bioactivity of TY2 in macrophage phagocytosis in a model of sepsis (FIG. 5A

[0200] Therapeutic benefits of TY2 in macrophage phagocytosis in sepsis. To further assess TY2 bioactivity on phagocytosis by bone marrow derived macrophages (BMDM) in sepsis, the in vitro assay used in Example 7 was performed.

[0201] Compared to vehicle treated cells, macrophage from both male (FIG. 7F) and female (FIG. 7G) mice exposed to 80nM of TY2 for 48 hours exhibited increased phagocytosis compared to macrophage exposed to 40nM TY2. Furthermore, phagocytosis peaked at 48 hours (FIG. 7H) indicating that the effects of TY2 are time dependent and show a transient effect.

[0202] These results show the effects of TY2 on macrophage phagocytose are concentration- and time-dependent.Example 11

[0203] This non-limiting example shows the therapeutic effects of TY2 on ventricular function in a model of arrhythmogenic cardiomyopathy (ACM).

[0204] Arrhythmogenic cardiomyopathy (ACM) is a potentially lethal inherited heart disease, with an estimated prevalence ranging from 1 in 2,000 to 1 in 5,000 individuals worldwide, making ACM rare but not ultra-rare. In the United States alone, this translates to approximately 60,000 to 200,000 affected individuals. ACM is a leading cause of sudden cardiac death in young adults and athletes.

[0205] ACM is characterized by progressive replacement of the ventricular myocardium with fibrofatty tissue, leading to ventricular arrhythmias, heart failure, and an elevated risk of sudden cardiac death.

[0206] Therapeutic benefits of TY2 in arrhythmogenic cardiomyopathy (ACM). Adult desmoglein 2 (DSG2) mutant mice, a model of ACM, were treated with intravenous TY2 or placebo two times a week and ventricular function was assessed (FIG. 8A). FIG. 8B shows representative M-mode (Motion-mode) echocardiograms from vehicle- and TY2-treated mice.

[0207] TY2 treatment improves right ventricular (RV) systolic function in DSG2 mutant mice. Ejection fraction percentage increased over time in TY2-treated mice compared to vehicle-treated mice (FIG. 8C). TY2 treatment also decreased Tricuspid Annular Plane Systolic Excursion (TAPSE) compared to vehicle treatment (FIG. 8D).

[0208] TY2 treatment improves ventricular electrical remodeling in DSG2 mutant mice. As determined by electrocardiogram (ECG) (FIG. 9A. representative image), TY2 treatment improved ventricular electrical remodeling compared to vehicle-treatment. TY2 treatment showed a decrease in QRS duration in female mice (FIG. 9B). Further, TY2 treatment reduced QT (FIG. 9C) and QTc (FIG. 9D) duration compared to vehicle-treatment.

[0209] TY2 treatment reduces ventricular arrhythmia susceptibility in DSG2 mutant mice. As determined by ECG (FIG. 10A, representative image of intracardiac pacing protocol), TY2 treatment reduced ventricular arrhythmia susceptibility compared to vehicletreatment as determined by quantification of intracardiac pacing-induced ventricular tachycardia (FIG. 10B).

[0210] TY2 treatment decreases spontaneous ventricular arrhythmias in DSG2 mutant mice. TY2 treatment decreased spontaneous ventricular arrhythmias (FIG. 11A) and ventricular arrhythmia burden over 24 hours (FIG. 11B) compared to vehicle-treatment.

[0211] TY2 treatment ameliorates conduction velocity and ventricular repolarization in DSG2 mutant mice. As determined by activation maps (FIG. 12A, representative activation map images), TY2 treatment increased ventricular conduction velocity (FIG. 12B) and reduced action potential duration at 80% repolarization (APD80) (FIG. 12C) compared to vehicle- treatment.

[0212] TY2 treatment reduces cardiac fibrosis in DSG2 mutant mice. TY2 treatment reduced expression of fibrosis marker genes compared to vehicle-treated mice (FIG.13A). TY2 treatment reduced ventricular interstitial fibrosis (FIG. 13C) but not ventricular perivascular fibrosis (FIG. 13D) as determined by Masson Trichome staining (representative images, FIG. 13B).

[0213] TY2 has anti-inflammatory and anti- arrhythmic effects that lead to striking reversal of ACM manifestations in DSG2 mutant mice. Given that ACM is defined by progressive interstitial fibrosis and adipose infiltration, TY2 may ameliorate disease by enhancing efferocytosis and limiting the expansion of fibrofatty scarring.Example 12

[0214] This non-limiting example shows the effects of TY2 on bone marrow derived macrophages (BMDM) from DSG2 mutant mice.

[0215] TY2 treatment modulates peripheral blood mononuclear cells (PBMC) from DSG2 mutant mice. Peripheral blood mononuclear cells (PBMCs) were isolated from desmoglein 2 (DSG2) mutant mice treated with intravenous TY2 or Vehicle (FIG. 14B) and gene expression levels were evaluated (FIG. 14A; schematic of the study design). TY2 levels were significantly higher in TY2-treated mice compared to Vehicle-treated mice (FIG. 14B).TY2 treatment reduced expression of Pickl (FIG. 14C) in PBMC, consistent with hyperphosphorylation of Smad3 (Example 9) observed in animals treated with TY2, and enhanced efferocytosis (FIGs. 15B, 15C; Example 2) observed in macrophages treated with TY2. Further, expression of IL6, an inflammation-related cytokine, was decreased (FIG. 14D) in TY2-treated mice compared to Vehicle-treated mice.

[0216] TY2 treatment increases in vitro efferocytosis in macrophage from DSG2 mutant mice. Bone marrow derived macrophage (BMDM) were isolated from desmoglein 2 (DSG2) mutant mice treated with intravenous TY2 or Vehicle, and in vitro efferocytosis was evaluated (FIG. 15A, schematic of the study design). TY2 treatment increased efferocytosis in BMDMs derived for DSG2 mutant mice compared to vehicle treated mice (FIG. 15B, representative images of efferocytosis assay, and FIG. 15C).Example 13

[0217] This non-limiting example shows results of an in vivo toxicity assay of TY2 in DSG2 mutant mice.

[0218] Absence of toxicity in DSG2 mutant mice following 6 weeks of systemic TY2 therapy. TY2 treatment did not significantly change endpoint body weight in in male or female TY2-treated mice compared to vehicle-treated mice (FIG. 16A) or serum laboratory values (FIG. 16B). Thus, the treated animals tolerated well systemic TY2 therapy over at least 6 weeks.

[0219] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

[0220] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in therelevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein structure without affecting the biological or chemical action in kind or amount. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.

[0221] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

Claims

WHAT TS CLAIMED TS:

1. An isolated nucleic acid comprising a nucleobase sequence comprising: (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90% identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the isolated nucleic acid is RNA, wherein the isolated nucleic acid is at most 35 nucleobases long, optionally wherein the nucleobase sequence does not include or is not CCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:1).

2. The isolated nucleic acid of claim 1, wherein the nucleobase sequence comprises CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO:2), or wherein the nucleobase sequence comprises CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:4).

3. The isolated nucleic acid of claim 1 or 2, wherein the isolated nucleic acid comprises at least one chemically modified residue, optionally wherein a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue.

4. The isolated nucleic acid of claim 3, wherein the isolated nucleic acid comprises 1-10 chemically modified residues.

5. The isolated nucleic acid of claim 3 or 4, wherein the isolated nucleic acid comprises at least one chemically modified residue within the 5’ half of the nucleobase sequence and / or at least one chemically modified residue within the 3’ half of the nucleobase sequence.

6. The isolated nucleic acid of any one of claims 3-5, wherein the chemically modified residue comprises a backbone modification.

7. The isolated nucleic acid of claim 6, wherein the backbone modification comprises a backbone sugar modification, optionally wherein the chemically modified residue is a locked nucleic acid (LN A).

8. The isolated nucleic acid of claim 6 or 7, wherein the isolated nucleic acid comprises the chemically modified residue at one or more of the first, third and fifth residuesfrom the 5’ end and the 3’ end of the nucleobase sequence, optionally wherein the nucleobase sequence comprises a LNA at the first, third and fifth residues from the 5’ end and the 3’ end.

9. The isolated nucleic acid of claim 6 or 7. wherein the nucleobase sequence comprises: CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein each of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleobase sequence is a LNA.

10. The isolated nucleic acid of any one of the preceding claims, wherein the nucleic acid is 26 nucleobases in length.

11. An isolated nucleic acid comprising a nucleobase sequence comprising (a) CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2); or (b) a variant nucleobase sequence at least 90% identical thereto with the proviso that when position 26 of the variant nucleobase sequence as numbered according to SEQ ID NO:2 is uracil, the variant nucleobase sequence comprises at least one other sequence variation relative to SEQ ID NO:2, wherein the nucleic acid is RNA.

12. The isolated nucleic acid of claim 11, wherein the nucleobase sequence is CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 2), or wherein the nucleobase sequence comprises CCCCCCCACUGCUAAAUUUGACUGGUU (SEQ ID NO:4).

13. The isolated nucleic acid of claim llor 12, wherein the isolated nucleic acid comprises at least one chemically modified residue, optionally wherein a residue of the isolated nucleic acid in the nucleobase sequence comprises the at least one chemically modified residue.

14. The isolated nucleic acid of claim 13. wherein the isolated nucleic acid comprises 1-10 chemically modified residue.

15. The isolated nucleic acid of any one of claims 13 or 14, wherein the isolated nucleic acid is at most 35 nucleobases long.

16. An isolated nucleic acid consisting of a nucleobase sequence: CCCCCCACUGCUAAAUUUGACUGGUA (SEQ ID NO: 5), wherein the nucleic acid is RNA, wherein each of positions 1, 3, 5, 22, 24, and 26 of the nucleobase sequence is a LNA.

17. A composition comprising:the isolated nucleic acid of any one of the preceding claims; anda pharmaceutically acceptable excipient.

18. The composition of claim 17, further comprising a transfection reagent.

19. The composition of claim 18, wherein the transfection reagent comprises one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC).

20. The composition of claim 17 or 18, wherein the transfection reagent comprises EV derived from cardiosphere-derived cells (CDC).

21. The composition of any one of claims 17-20, comprising a casein phosphoprotein.

22. The composition of any one of claims 17-21, comprising chitosan.

23. The composition of any one of claims 17-22, wherein the isolated nucleic acid is encapsulated in a casein-chitosan complex.

24. The composition of any one of claims 17-23, comprising casein micelles.

25. A macrophage comprising the isolated nucleic acid of any one of claims 1-16, wherein a cytoprotective activity of the macrophage is increased compared to a macrophage without the isolated nucleic acid.

26. The macrophage of claim 25, wherein the macrophage is in a subject.

27. The macrophage of claim 25, wherein the macrophage is in culture.

28. The macrophage of any one of claims 25-27, wherein the cytoprotective activity comprises efferocytosis and / or phagocytosis.

29. A kit comprising:the nucleic acid of any one of claims 1-16; anda transfection reagent.

30. The kit of claim 29, wherein the transfection reagent is one or more of a liposome, an extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC).

31. The kit of claim 29 or 30, comprising: a casein phosphoprotein and / or chitosan.

32. The isolated nucleic acid of any one of claims 1-16 or the composition of any one of claims 17-24 for use in a method of treating a heart condition or symptom thereof, the method comprising administering to a subject in need of treating the heart condition or symptom thereof a therapeutically effective amount of the isolated nucleic acid or the composition, thereby treating the heart condition or symptom thereof.

33. The isolated nucleic acid or composition for use of claim 32, wherein the heart condition comprises:a symptom and / or sequelae of heart failure;myocardial infarction (MI);a symptom or sequelae of an infection, optionally wherein the infection comprises sepsis; orarrhythmogenic cardiomyopathy (ACM).

34. The isolated nucleic acid or composition for use of claim 32 or 33-38, wherein the subject, before the administering, has one or more of: elevated E / e’ ratio, decreased ejection fraction, increased bacterial load in the heart and / or lungs, enlarged spleen, wasting, elevated serum lactate and / or aspartate transferase (AST) levels, elevated cytokine levels in the heart and / or lungs, increased frequency of ventricular arrhythmias, decreased cardiac conduction velocity, increased QRS, QT, QTc and / or action potential duration at 80% repolarization.

35. The isolated nucleic acid or composition for use of any one of claims 32-34, comprising identifying the subject in need of treating the heart condition or symptom thereof.

36. The nucleic acid of any one of claims 1-16 or the composition of any one of claims 17-24 for use in a method of treating an inflammatory or fibrotic condition, the method comprising administering to a subject in need of treating the inflammatory or fibrotic condition a therapeutically effective amount of the isolated nucleic acid or the composition, thereby treating the inflammatory or fibrotic condition.

37. The isolated nucleic acid or composition for use of claim 36, wherein the inflammatory condition comprises an infection and / or symptom or sequelae thereof, optionally wherein the infection comprises sepsis.

38. The isolated nucleic acid or composition for use of claim 37, wherein the symptom or sequelae of the infection comprises heart and / or lung dysfunction.

39. The isolated nucleic acid or composition for use of any one of claims 36-38, comprising identifying the subject in need of treating the inflammatory or fibrotic condition.

40. The isolated nucleic acid or composition for use of any one of claims 36-39, wherein the inflammatory condition comprises immunosuppression subsequent to a hyperinflammatory response.

41. The isolated nucleic acid or composition for use of claim 36, wherein the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.

42. The isolated nucleic acid or composition for use of any one of claims 32-40, (a) wherein the therapeutically effective amount of the isolated nucleic acid comprises from about 0.001 mg / kg to about 100 mg / kg, or 0.01-1000 nM;(b) wherein the method comprises administering the therapeutically effective amount of the isolated nucleic acid or the composition no more frequently than twice a week; and / or (c) wherein the method comprises administering the therapeutically effective amount of the isolated nucleic acid or the composition intravenously, intramuscularly, intracardially, or orally.

43. The isolated nucleic acid of any one of claims 1-16, or the composition of any one of claims 17-24, for use in a method of immunomodulation, the method comprising contacting an effective amount of the isolated nucleic acid or the composition with a population of macrophages, to thereby modulate an anti-inflammatory activity of macrophages of the population.

44. The isolated nucleic acid or composition for use of claim 43, wherein the contacting comprises administering to a subject in need of treating an inflammatory condition the effective amount of the isolated nucleic acid or the composition, to thereby modulate an anti-inflammatory activity of macrophages in the subject.

45. The isolated nucleic acid or composition for use of claim 43 or 44, wherein the macrophage is a human macrophage.

46. The isolated nucleic acid or composition for use of any one of claims 43-45, wherein contacting the effective amount of the isolated nucleic acid or the composition with the population of macrophages:reduces PICK1 expression in the macrophages;reduces IL6 expression in the macrophages; and / orincreases macrophage phagocytosis.

47. The isolated nucleic acid of any one of claims 1-16 or the composition of any one of claims 17-24 for treatment of a heart condition or symptom thereof in a subject in need thereof, optionally wherein the heart condition comprises myocardial infarction (MI) or arrhythmogenic cardiomyopathy (ACM).

48. The isolated nucleic acid of any one of claims 1-16 or the composition of any one of claims 17-24 for treatment of an inflammatory and / or fibrotic condition in a subject in need thereof, optionally wherein the inflammatory condition comprises sepsis and / or a symptom or sequelae thereof, or the fibrotic condition comprises cardiac fibrosis and / or pulmonary fibrosis.